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A STUDY OF SERUM SOLUBLE CD 40 LIGAND LEVEL IN PATIENTS WITH 
                                         ACUTE CORONARY SYNDROME 
ABSTRACT 
Introduction: 
     Coronary heart disease is an impairment of heart function due to inadequate blood 
flow to the heart. It is the most common cause of death worldwide by 2020. Serum 
sCD40L  is an inflammatory marker. It is released from the platelets as soon as the onset 
of the chest pain. It is a strong predictor of cardio vascular risk factor.  
Aims and Objectives 
    To estimate Serum sCD40Ligand, Serum CK-MB, Serum Lipid Parameters, Serum 
LDH, and Serum AST levels in patients with ACS.  
Materials and methods 
      Study group comprised of 50 subjects were admitted in ICCU with ACS (33ST 
elevation MI, 4 Non ST elevation MI, 13 UA). 50 healthy sex and age matched subjects 
were taken as control groups. Venous blood samples were collected. Serum Soluble 
CD40Ligand was estimated by ELISA technique, Serum CK-MB estimated by Immuno-
inhibition method, Serum Lipid profile by enzymatic assay methods. Serum LDH by 
DKGC method, Serum AST by Modified IFCC method. 
Results 
       Serum sCD40L(p<0.0001), Serum TC, Serum TGL, Serum LDL-C, Serum VLDL 
were significantly increased in the study group, significant decrease in Serum HDL-C 
(p<0.0001)  in study group compared to control group. By using pearsons correlation 
there is positive correlation between Serum sCD40L and Serum CK-MB, Serum TC, 
Serum TGL(p<0.01) and negative correlation between Serum sCD40L and Serum HDL-
C (p<0.01). 
Conclusion 
   sCD40L can be used as a marker in individuals with Acute Coronary Artery disease. 
Key words: sCD40L, ACS, MI, CK-MB, Lipid Parameters.     
                                      INTRODUCTION 
  
 Coronary heart disease (syn: ischaemic heart disease)-is defined as 
cardiac function impairment. There is an inadequate blood flow in the heart 
compared to its needs and obstructive changes in the coronary circulation  
(1982)(1).                                       
CHD is a world wide health epidemic. All over the world it is the 
commonest cause of death. In USA, European countries, Japan, Singapore, 
Canada etc, this is the first common cause of death. In India it is one in ten 
common causes of death(2). Epidemics of CHD in United States, began in the 
early 1920s, in the 1930s in the Britain, still later in several European 
countries(1) . 
World wide cardiovascular death is about 30 percent. Of which CHD is 
more than half. CHD has been classified as Acute Coronary Syndrome, 
Chronic CHD, and sudden death. Clinically in many ways CHD may present, 
extending from an asymptomatic finding to unexpected cardiac collapse. 
Chronic CHD is always secondary to coronary atherosclerosis, leading 
to coronary blood flow mismatch and adenosine triphosphate homeostasis                                                                              
(imbalance of demand and supply) and coronary ischaemia. Acute coronary 
syndrome is a unifying term representing a common end result, acute 
myocardial ischaemia. 
Acute ischaemia is usually caused by atherosclerotic plaque rupture, 
erosion, fissuring, or a combination with superimposed intracoronary 
thrombosis and is associated with an increased risk of myonecrosis and cardiac 
death. It encompasses acute myocardial infarction and unstable angina 
(resulting in ST elevation or non- ST elevation). 
ACS in emergency department should be triaged immediately to an area 
with defibrillation capability and continuous electrocardiographic monitoring(3). 
.
 
       Diagnosis of ACS at this earlier stage can prevent morbidity and 
mortality. Along with ECG changes, proteins in the serum like CK-MB, 
Cardiac Troponin-I &T, LDH and AST are used to diagnose ACS. However, in 
the absence of necrosis these markers are not elevated when measured in the 
first 2-6 hours following an ischemic event. 
    
     Serum sCD40 Ligand – is a type II transmembrane glycoprotein .It is  
structurally related to Tumour Necrosis Factor -alpha. It is expressed within 
seconds after platelet activation and it has been shown to be proinflammatory 
for endothelial cells, which ultimately lead into endothelial dysfunction and 
atherosclerosis. 
              Hence in the present study, serum levels of sCD40L were estimated in 
patients with ACS and the relationship between Serum sCD40L, Serum CK-
MB and lipid profile were analyzed.  
 
 
 
 
 
 
 
 
 
 
 
                                                             
                                                             
REVIEW OF LITERATURE 
 
Ischaemic Heart Disease is due to inadequate supply of oxygen and 
blood flow to the myocardium. There is an imbalance between demand and 
myocardial oxygen supply, mainly due to epicardial coronary artery 
atherosclerosis. Because of arterial involvement myocardial perfusion is 
impaired. There is regional reduction in myocardial blood flow. 
Epidemiology:   
IHD causes more deaths, disabilities, and economic losses. It occurs 
mainly in the developed countries than any other illness. 
In US IHD is the most life threatening, chronic and serious illness. 
Incidence of MI is >7 million and of IHD is >13 million and of Angina pectoris 
is >6 million. 
  Emergence of IHD is associated with energy rich and a high fat diet, 
smoking and sedentary life style. In the Western Europe and United States, it 
occurs more in low socioeconomic group of people,  progression of disease can 
be  delayed by primary prevention . 
  Risk factors for IHD are Obesity, Type 2 Diabetes Mellitus and insulin 
resistance. In South Asian countries, especially in India, the population 
subgroups particularly affected by IHD are men. 
By 2020, IHD is the most common cause of death worldwide(4,5). 
 
 
Classification of ischaemic heart diseases: 
   Ischaemic heart disease divided into two groups: 
    1. Acute coronary syndrome                                                               c                
    2. Chronic  coronary artery disease 
 
Risk factors for Acute Coronary syndrome: 
 I) Major risk factors:                                                                                                                                                                                                   
A) Modifiable: 
1) Dyslipidaemia 
2) Hypertension 
3) Diabetes mellitus 
4) Smoking 
 
B) Constitutional: 
1) Age 
2) Sex 
3) Genetic factors  
4) Familial and Racial factors 
 
II) Emerging risk factors: 
1) Environmental influences 
2) Obesity 
3) Hormones- Oestrogen deficiency, Oral Contraceptives 
4) Physical inactivity 
5) Stressful life 
6) Homocystinuria 
7) Role of alcohol 
8) Prothrombotic  factors 
9) Infections (Chlamydia Pneumonia, Herpes virus, Cytomegalo virus) 
10) High  C- Reactive protein 
11) Other dietary habits 
12) Social deprivation 
 
Dyslipidemia: 
Chronic dyslipidemia initiates endothelial injury and dysfunction and 
causes increased permeability. Hypercholesterolemia with increased serum 
concentration of LDL promotes formation of foam cells(6,7). 
 
Hypertension:   
 Incidence of atherosclerosis is more with elevated blood pressure.  
 Hypertension doubles the risk of all forms of cardiovascular diseases. 
Mechanical injury to the arterial wall is due to increased blood pressure.  
Elevation of diastolic blood pressure more than  95 mm of Hg and 
Systolic blood pressure more than  160 mm of Hg is associated with five times 
the increased risk of  developing IHD than in people with blood pressure within 
normal range(140/90 mm of Hg or less)(6,8).  
Diabetes Mellitus: 
In people with type I and Type II Diabetes Mellitus, clinical 
manifestations of atherosclerosis are far more common and develop at an early 
age. 
The risk of developing IHD is doubled in Type 2 DM. Endothelial 
dysfunction, increased aggregation of platelets, increased LDL-C, and 
decreased HDL-C are the causes of increased severity of atherosclerosis. 
Glucose intolerance accounts for a major part of the high incidence of ischemic 
heart disease in certain ethnic groups, (eg): South Asians(9). 
 
Smoking: 
In smokers, the extent and severity of atherosclerosis are much greater 
than in non-smokers. Cigarette smoking is associated high risk of 
atherosclerotic IHD and sudden cardiac death. 
Men who smoke a pack of cigarettes per day are 3-5 times more risk to 
die of IHD than non-smokers. 
The increased risk of atherosclerosis in smokers could be attributed to 
the following factors: 
• Altered serum lipids (Elevated LDL-C and reduced HDL-C 
levels). 
• Accumulation of carbon monoxide in the blood produces 
carboxy haemoglobin which in turn favours atherosclerosis by 
producing hypoxia in the arterial wall. 
• Increased platelet aggregation and vasospasm produced by 
nicotine- reduces myocardial oxygen supply. 
• Smoking causes release of catecholamines which increases heart 
rate and blood pressure and myocardial oxygen demand(10).  
 
 
 
Constitutional risk factors: 
Age: 
Atherosclerosis is an age related disease. In childhood, early lesions of 
atherosclerosis may be present whereas clinically significant lesions are found 
in the fourth decade. Beyond fourth decade, fully developed atheromatous 
plaques appear.   
 
Sex: 
Premenopausal women have lower rates of disease than men. In females 
it is due to high level of oestrogen and high density lipoprotein, both of which 
have anti-atherogenic influence. After the menopause this sex difference 
disappears. The incidence and severity of atherosclerosis are more in men than 
women and changes appear a decade earlier in men (>45 years) than women 
(>55 years). 
The prevalence of atherosclerotic IHD is about three times higher in 
men in 4th decade than  women and the difference slowly declines with age but 
remains higher at all ages in men(11,12). 
 
Genetic factors: 
There is genetic derangement of lipoprotein metabolism. It leads to high 
serum lipid levels and familial hypercholesterolemia. 
 
 
 The impact of genetic risk  of CHD in twins-a monozygotic twins are  
eight fold increased risk, and a dizygotic twins are fourfold increased risk of 
dying from CHD compared to general population(6,10). 
Familial and Racial factors: 
Familial predisposition to atherosclerotic vascular disease, mainly 
depends on combination of genetic, environmental and lifestyle factors. The 
familial predisposition to atherosclerosis may be related to other risk factors 
like DM, HT, Hyperlipoproteinemia. 
A Cases can be diagnosed when clinical problems occur at a relatively 
young age (<50 years for men and <55 years for women) in the first degree 
relatives.  Racial differences too exist; Blacks have generally less severe 
atherosclerosis than Whites(8,10). 
 
Emerging risk factors: 
1.   Enviromental influences: 
        Higher incidence of atherosclerosis in developed countries and low 
incidence in underdeveloped countries suggest the role of environmental 
influences. 
 
 
 
 
2. Obesity: 
If the person is overweight by 20% or more, it is associated with 
increased risk. Atherosclerosis is more likely related to android or upper 
body obesity than to general obesity(7). 
 
3. Hormones: 
Oral contraceptive administration or endogenous oestrogen deficiency 
(eg: in post menopausal women) has an increased risk of developing 
Myocardial Infarction or Stroke. 
 
4. Physical inactivity:                                                                                                                                        
The risk of CHD is doubled by physical inactivity.  Regular exercise has 
been shown to have a protective effect by increasing in serum HDL-C 
levels, lowering the blood pressure and development of collateral vessels.  
 
5. Stressful life style: 
This is termed as Type A behavior pattern and is characterized by  
aggressiveness , competitive drive, ambitiousness and sense of urgency. It 
is associated with enhanced risk of IHD when compared with Type B 
behavior of relaxed and happy –go –lucky type. 
 
 
 
 6. Homocysteinemia: 
It is an uncommon inborn error of metabolism, which can present with 
early atherosclerosis and CHD(13). 
 
7. Alcohol: 
  Excess alcohol consumption is associated with HT and Cerebrovascular 
disease(14). 
 
8. Prothrombotic factors:  
Platelet activation and elevated fibrinogen level are associated with 
increased risk of Coronary thrombosis which is the gravest complication 
of atherosclerosis. Antiphospholipid antibodies are associated with 
recurrent arterial thrombosis(10,15,16). 
 
9. Role of infections: 
 Chlamydia Pneumonia and viruses such as Herpes virus and 
Cytomegalovirus have been found in coronary atherosclerotic lesions. In 
combination with some other factors they cause inflammation and 
atherosclerosis(17,18,51). 
 
 
 
10. C-Reactive protein:  
It is an acute phase reactant and it correlates with the risk of developing 
atherosclerosis(9,16). 
11. Dietary products: 
      Diets deficient in vegetables, fresh fruits and polyunsaturated fatty acids are 
associated with increased cardiovascular risk. Mediterranian diet has been 
shown to reduce cardiovascular events. Dietary supplements such as vitamins 
C, E, Beta-Carotene, Folate, and Fish oils  reduce cardiovascular events.  
 
12.  Social deprivation:  
Health inequalities also have a major influence on cardio vascular 
disease(9). 
Clinical Types of IHD: 
    Patients with IHD can be divided into two groups 
1) Chronic coronary artery disease 
2) Acute Coronary Syndrome 
Chronic Coronary Artery Disease: 
It is always secondary to coronary atherosclerosis, leading to mismatch 
of coronary blood flow and ATP homeostasis (imbalance of supply and 
demand) and a stable pattern of coronary ischemia. The clinical pattern 
includes stable angina pectoris and Myocardial Infarction. 
 
 
Angina: 
Blood flow to the heart muscle does not provide an adequate supply of 
oxygen for its requirements. As a result, cardiac muscle becomes ischemic and 
chest pain occurs. 
Pain is substernal, central crushing in nature and may radiate to arms, 
neck or jaw(17). 
Angina may be of different types: 
 
1) Stable Angina:  
            It is due to vasoconstriction which can be evoked by intense 
sympathetic stimulation. Example: severe stress or severe cold or by narrowing 
of a coronary artery due to atheroma(18). 
  
2) Variant Angina ( Prinzmetals Angina): 
It is caused by coronary vasospasm. In this type angina occurs at 
rest with reversible ST segment elevation without enzymatic evidence of 
MI(19). 
 
 
     3)Heberdens Angina: 
Myocardial ischemia is induced by increased myocardial 
contraction acting in the face of the relatively constant coronary blood 
flow prescribed by structural coronary stenosis produced by 
atherosclerosis(20). 
 4)Other Anginal Types: 
1. Nocturnal Angina: Angina occurs during sleep at night due to 
coronary ostial stenosis. 
2. Angina Decubitus:  Angina occurs in recumbent position 
3. Stable exertional Angina: Angina occurs predictably at a certain 
level of exertion. 
4. Unfamiliar tasks: Angina may also be precipitated by heavy meal, 
exposure to cold etc. 
            
             MANIFESTATIONS OF ACUTE CORONARY SYNDROME 
 
 
 
 
 
 
 
 
 
 
 
Acute Coronary Syndrome: 
ACS is a unifying term representing a common end result, acute 
myocardial ischemia. It is caused by rupture, erosion or fissuring of an 
atherosclerotic plaque which can occur alone or in combination with 
intracoronary thrombosis. This is associated with an increased risk of 
myocardial necrosis(21). 
It encompasses ischemia with minimal myocardial damage that is 
unstable angina and Acute Myocardial Infarction(22,23). 
 
Acute Myocardial Infarction may be  
 1) STEMI (ST elevation Myocardial Infarction) 
2) NSTEMI (Non ST elevation Myocardial Infarction) 
Recognizing a patient with ACS is important because the diagnosis 
triggers both triage and management. ACS in the emergency department should 
be triaged immediately to an area with continuous electrocardiographic 
monitoring and defibrillation capability. 
An ECG should be obtained and accurately interpreted within 10 
minutes. Patients with suspected ACS should be managed immediately with 
antiplatelet and anticoagulant therapies and considerable for immediate 
revascularization mechanically or pharmacologically if new ST elevation is 
noted. ACS is a life threatening condition. 
Proper initial triage of patients suspected to have coronary ischemia 
should eventually identify patients as having 
(1)  Acute Coronary Syndrome. 
(2) Non-ACS cardiovascular conditions such as Myocarditis, Myo 
pericarditis and also Cardiomyopathy related to Stress, Aortic 
Dissection or Pulmonary Embolism. 
(3) A non-cardiac cause of chest pain such as gastro oesophageal reflux. 
(4) A non-cardiac condition such as Sepsis. 
ACS patients with new evidence of ST elevation on ECG are labeled as 
having STEMI and should be considered for immediate reperfusion therapy by 
percutaneous coronary intervention or thrombolytics.    
NSTEMI patients present without ST elevation and have evidence of 
myonecrosis. Unstable Angina patients do not have any evidence of 
myonecrosis. 
 
Unstable Angina:                                                                           
Unstable Angina (or) Cresendo Angina (or) Preinfarction Angina: It is 
defined as rest pain without a recent myocardial infarct (Braunwald class IIIB) 
and no evidence of major myocardial necrosis as reflected by raised serum 
Creatine Kinase MB. Transient ST-T segment depression and T wave inversion 
are often present in this group of patients(24).     
 Fissuring of plaques causes sudden onset of angina which increases in 
frequency and severity. There is subsequent total thrombotic occlusion of the 
vessel. Unstable angina will progress to MI or death may occur due to 
secondary development of a ventricular arrhythmia(25,26).  
 
Myocardial Infarction: 
Irreversible necrosis of part of the heart muscle is almost always due to 
Coronary atherosclerosis. ECG abnormalities are  
1)  Inverted T wave due to ischemia 
2) ST abnormalities due to muscle injury  
3) Pathological Q wave due to muscle death. If coronary blood flow is 
interrupted, myocyte necrosis occurs for an extended period of time.  
 
Pathologically – There are two types of MI 
1. Subendocardial MI 
2. Transmural MI 
In MI plaque, there is progression, disruption, subsequent clot 
formation. The thrombus is quite stable and occludes the vessel for a prolonged 
period, ultimately causing progression of myocardial ischemia to myocyte 
necrosis and death(27).  
 
ST segment elevation MI: 
In this condition, a completely occlusive thrombus results in total 
cessation of coronary blood flow in the territory of the occluded artery. It is the 
most stable form of ACS. Full or nearly full thickness necrosis of the 
ventricular wall supplied by the occluded artery leads to formation of new Q 
wave .  
 
The actual diagnosis of STEMI is not completely based on ECG 
findings. The classic WHO criteria for an acute myocardial infarction  requires 
the two of the following three elements to be present:  
(1) A history suggestive of coronary ischemia for a prolonged period of 
time (>30 minutes) 
 (2) A rise and fall in serum cardiac markers with myonecrosis. 
(3) Evolutionary changes on serial ECGs suggestive of MI 
(3) A rise and fall in serum cardiac markers with myonecrosis(3). 
 
Non ST segment elevation MI: 
Patients with clinical features of unstable angina develop evidence of 
myocardial necrosis which is diagnosed by elevated cardiac biomarkers. The 
ECG show no ST elevation, T wave inversion, and ST depression exceeding  
2 mm. 
 
 
 
 
 
 
 
 
 
PATHOPHYSIOLOGIC EVENTS IN ACUTE CORONARY  
SYNDROME 
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PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROME: 
Rather than the degree of stenosis, atherosclerotic plaque composition 
and non stenotic lesions are more frequently implicated in ACS. Non occlusive 
plaques become complicated by thrombus and progress rapidly to total 
occlusion. 
 ACS is due to five main causes: 
1. Plaque rupture with acute thrombosis by formation of blood clot that 
gradually occludes the lumen is the pivotal event in atherothrombotic 
process. 
2. Progressive increase of plaque volume leads to mechanical obstruction. 
3. Inflammation by growth factors and enzymes, local and systemic 
production of mediators of cytokines activate the plaque and disrupt the 
fibrous cap. 
4.  Coronary vasoconstriction occurs due to dynamic obstruction 
influenced by endothelial dysfunction. 
5. Plaque embolization occurs at distant level from atherothrombotic 
coronary occlusion(28). 
In most cases of ACS, sudden luminal thrombosis is a consequence of 
either plaque rupture, plaque erosion, or a calcified nodule. 
Prolonged chest pain at rest often results from fissuring or rupturing of 
the atherosclerotic plaque leading to thrombus formation. 
Plaques are prone to rupture which contain large amounts of 
extracellular cholesterol covered by a thin cap of fibrotic tissue. The immediate 
site of plaque rupture is marked by an inflammatory process (macrophage rich 
area). 
The inflammation plays a role in destabilizing the fibrous cap tissue. 
Factors predisposing to plaque rupture are circulating immune complexes, 
nicotine, hyperlipidemia, high angiotensin level, elevated acetoacetic acid 
levels in diabetes. The junction between the normal and atherosclerotic 
segments of an eccentric stenosis is the site for rupture of the fibrous cap(29,30).  
 
 Atherosclerosis: 
It is a Greek word; Sclerosis means hardening. Coronary artery disease 
and MI are the number one killers in the world .In India 20% of deaths are due 
to CAD and Myocardial ischaemia. 
It is estimated that by the year 2020, it  will account for 33% of all 
deaths(31). Atherosclerotic lesions were graded according to the types of lesion 
by the American College of Cardiology/American Heart Association 
classification. 
 Type A lesions are defined as discrete lesions (<10 mm in length).  
Type B lesions are tubular lesions (10-20 mm in length) 
Type C lesions are diffuse lesions (> 2 cm in length)(24).          
Atherosclerosis represents a chronic inflammatory response to vascular 
injury and activate endothelium and promote lipoprotein infiltration, 
modification and retention combined with inflammatory cell entry, retention 
and activation(32).  
 Atherosclerosis can affect any artery in the body. In the heart, it may 
cause angina, MI and sudden death. In the brain, it may cause stroke and 
transient ischemic attack. In the limbs, it may cause claudication and critical 
limb ischemia(33).                                                                                                                                                                                              
                               
                            PATHOGENESIS OF ATHEROSCLEROSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS: 
Endothelial injury is the initiating event in atherosclerosis. Endothelial 
injury is caused by hypertension, hypercholesterolemia, local hemodynamic 
abnormalities, cigarette smoking, hyperhomocysteinemia, increased LDL-C , c-
reactive protein, increased fibrinogen, insulin resistance ,oxidative stress, 
infections like Herpes virus or Chlamydia pneumonia, periodontal diseases and 
combination of these factors(34,35). 
Endothelial dysfunction is due to the accumulation of macrophages. 
These are derived from lipids and circulating  monocytes (predominantly LDL-
C). At the site of vascular injury, oxidation of low density lipoproteins and 
their ingestion by macrophages produces foam cells. The foam cells aggregate 
to form the fatty streak, the earliest visible lesion of atherosclerosis. 
The atherosclerosis is a complex disease involving increased pro-
oxidant stress, inflammatory fibro-proliferative and angiogenic responses 
combined with smooth muscle cell proliferation which results in plaque 
formation(36). 
 
Theories of atherogenesis: 
Atherogenesis is the major cause of cardiovascular disease, due to the 
formation of atheroma which leads to arterial hardening. Several theories have 
been put forward. 
 The response to injury hypothesis of Ross: 
Arterial vessel wall (Endothelial ) injury is the main hypothesis and 
interaction of platelets with damaged vessel wall. 
Endothelial injury due to a number of different risk factors, which 
include viral infection, hyperlipidemia, and smoking(11). 
 
The lipid oxidation hypothesis of Steinberg and Collegues: 
This hypothesis suggests that mechanism of endothelial injury and  
formation of macrophage derived foam cells that are characteristic of the early 
lesions of atherosclerosis. 
Leucocytes adhesion to endothelium and subsequent accumulation of T 
lymphocytes and monocytes in subendothelial space. Within the arterial wall 
the monocytes are converted to lipid laden foam cells and form 
macroscopically evident  fatty streak lesion. 
                          
 
                       PROGRESSION OF CORONARY LESIONS LEADING TO ACS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Course of atherosclerosis: 
 
Accumulation of low density lipoprotein particles in the intima is the 
initial step leading to fatty streaks.  
 Fatty streaks are formed when inflammatory cells, predominantly 
monocytes binds to endothelial cell receptors and migrate into the intima. They 
then develop into lipid laden macrophages or foam cells by taking up oxidized 
LDL-C that are universally present in atheromatous plaques(37,38,39). 
 
           Extra cellular lipid pools appear in the intimal space when these foam 
cells die and release their contents.  
         
          Activated macrophages produces growth factors and cytokines. There is 
migration of smooth muscle cells into the intima of the arterial wall from the 
media. Macrophages also stimulates smooth muscle cell proliferation. Oxidized 
LDL can induce production of  Vascular Cell Adhesion Molecule (VCAM-1) -
1,Intra Cellular Adhesion Molecule-1(ICAM-1) which can lead onto increase 
in size of the plaque(40). 
 
Cytokines such as Tumour Necrosis Factor-alpha, interleukin, interferon 
–gamma, platelet derived growth factor and matrix metalloproteinases are  
released by activated macrophages. They cause degradation of collagen cross-
struts within the plaque and senescence of the intimal smooth muscle cells 
overlying the plaque(41). 
This results in thinning of the protective fibrous cap and thereby causing 
the lesion vulnerable to mechanical stress. This in turn causes fissuring, erosion 
or rupture of the surface of the plaque. 
If there is any breach in the integrity, the contents of the plaque will be 
exposed into the blood. Thus will trigger platelet aggregation and thrombosis 
and extend into the arterial lumen(42,43,44). 
      
      PROGRESSIVE DEVELOPMENT OF ATHEROSCLEROTIC 
PLAQUE 
 
 
 
 
 
                     
 
                        PLAQUE RUPTURE AND ATHEROT
 
 
 
 
 
 
 
 
 
HROMBOSIS 
 Acute changes in plaque fall into three general categories:  
 
1) Rupture/fissuring –exposing highly thrombogenic plaque constituents 
and subsequent thrombosis. Such thrombosis can partially or completely 
occlude the lumen and lead to downstream ischemia.  
 
2) Erosion/ulceration exposing the thrombogenic sub-endothelial 
basement membrane to blood.  
 
3) Hemorrhage into the atheroma expanding its volume. Rupture of the 
overlying fibrous cap or the thin walled vessels in the areas of 
neovascularization, can cause intra plaque hemorrhage. A contained hematoma 
may expand the plaque or induce rupture of the plaque. 
             
            Atheroembolism- Plaque rupture can discharge atherosclerotic debris 
into the blood stream, producing micro emboli(41). 
 
       Role of sCD40ligand in Atherogenesis: 
Atherogenesis is due to CD40/CD40L interaction on the endothelial cell 
surface. This results in endothelial and smooth muscle cell activation and 
subsequent expression of adhesion molecules(51).  
CD40L promotes interactions of dentritic cells and T-lymphocytes 
within the vessel wall. Mapping of activated dentritic cells in coronary 
atheroma and human carotid artery showed that CD40L affects dentritic cells 
and regulate T-cell infiltration, which in turn all required for formation of 
unstable coronary atheroma(45). 
sCD40L activates specific redox sensitive pathways and thereby has an 
unfavorable effect on endothelium dependent relaxation and vascular redox 
state.CD40L increases vascular oxygen production by destabilizing the 
messenger ribonucleic acid of endothelial NO synthase(46). 
Therefore pro-inflammatory cytokines, reduced NO bioavailability and 
over expression of adhesion molecules promote requirement of leucocytes and 
migration into the media of vessel wall, thereby formation of atheroma. 
Interaction between CD40L and CD40 also affect the release of 
adipokines from adipocytes contributing to atherogenesis(47).  
 
         CD40L is expressed by activated platelets. It is then cleaved and released 
and sCD40L binds to circulating monocytes through monocyte / macrophage 
integrin MAC-1 and CD40Lreceptor and thereby promote adhesion of 
circulating monocytes to the vascular endothelium(48).  
       
 sCD40L also binds to endothelial cell surfaces CD40Lreceptor and 
activates it. This triggers the over expression of transcriptional factors such as  
Activator Protein-1( AP-1), nuclear factor   kappa B and others to express 
adhesion molecules such as  Intracellular Adhesion Molecule-1(ICAM-1), 
 E-Selectin and Vascular Adhesion Molecule-1(VCAM-1) on the surface of   
Endothelial cells(49). 
CD40/CD40L AND ATHEROTHROMBOSIS 
 
Adhesion and transmigration of monocytes to subendothelial space is 
mediated by these molecules. Smooth Muscle Cells and activated endothelial 
cells also produce proinflammatory molecules such as interleukins and 
Monocyte Chemoattractant Protein-1(MCP-1). These molecules over express 
Reactive Oxygen Species (ROS) generating enzymes and also release 
prothrombotic mediators like tissue factor(50). 
The ROS oxidize LDL to oxidized LDL (Ox-LDL) which is taken up by 
activated macrophages which are turned into foam cells(51,52,53). sCD40L also 
activates fibroblasts and smooth muscle cells. They are proliferated and 
migrate to further induce atherogenesis. sCD40L regulates the development 
and stability of thrombus in ACS. This stability is maintained by the interaction 
between the lysine-arginine glutamic acid domain of the sCD40L and platelet α 
II b/β3 receptor(54). 
      CD40/CD40L interactions induce the expression of matrix 
metalloproteinases that degrades thin fibrous cap of atheromatous plaques and 
interstitial collagen, leading to plaque instability and rupture(47). 
Circulating sCD40L levels are higher in AMI and Unstable angina, 
compared with healthy persons. Gradual increase in sCD40L level takes place 
with ACS progression(55,56). 
 Platelets are the main source of sCD40L, being responsible for 95% of 
the circulating sCD40L levels(57).      
 Carriers of 807 T polymorphism on the GP Ia gene which regulates 
surface density of the receptor, express higher sCD40L levels during the acute 
phase of MI(58).  
Compared to healthy individuals plasma sCD40L is higher in patients 
with  stable angina(59). 
 
 
 
 
 
 
                                       STRUCTURE OF SCD40 LIGAND
 
 
 
 
 
 
 
 
 
 Soluble CD40Ligand :: 
           Soluble CD40 ligand is a homotrimeric Type II transmembrane 
glycoprotein that is related structurally to Tumour Necrosis Factor-alpha(80). It 
was first identified on activated platelets and on CD4+cells.Tumour Necrosis 
Factor homology domain is present in its carboxy terminus which is required 
for binding to its receptor CD40.  
           Platelet activation expresses CD40L on platelet membranes. sCD40L, an 
18 kDa soluble fragment is produced by subsequent cleavage by 
metalloproteases. sCD40L binds to CD40 receptor in the endothelial membrane 
and lead into inflammatory process amplification. 
         Increased serum sCD40L concentration due to platelet activation has been 
associated with acute and stable coronary artery disease, chronic inflammatory 
bowel disease and hypercholesterolemia. Platelet activation is important for 
thrombus formation which precipitates most of the unstable coronary 
syndromes(60,61,62,63).   
           sCD40L plays a crucial role in the pathogenesis of atherosclerosis and 
coronary artery disease and has been shown to be a promising clinical 
biomarker of atherothrombotic risk. Soluble form of CD40L and CD40 acts as 
a mediator between vascular endothelium, platelets and other cell types(50,64,65). 
             Elevated concentrations of sCD40L causes increased expression of 
CD40 receptor in human coronary artery endothelial cells. This process is 
mediated by extra cellular signal related kinase (ERK)1/2 .Amplification of 
sCD40L levels produces increased platelet activation and endothelial 
dysfunction in coronary endothelium(66).  
        sCD40L contributes to atherosclerotic plaque progression by inducing the 
expression of chemokines, cytokines,  matrix metalloproteinases, growth 
factors and procoagulant factors in various atheroma associated cell types(67,68). 
       In vivo platelet activation can be sensitively marked by monocyte-platelet 
aggregates than P-selectin. Even before the onset of myocardial necrosis, 
markers of platelet activation can identify the disease activity. sCD40L plays 
an important  role in plaque stabilization and disease progression(57). 
         sCD40L promotes coagulation by induction of tissue factor expression on 
monocytes and endothelial cells and is proinflammatory for endothelial cells. 
Compared to healthy individuals and patients with stable angina, those with 
unstable angina have been shown to have sCD40L concentrations. This is 
because of sCD40L release from activated T lymphocytes or platelets(69). 
         CD40-CD40L system has been implicated in the pathophysioplogy of 
various chronic inflammatory diseases(50,70,71). 
 
 
 
STRUCTURE OF CD40 RECEPTOR, CD40L AND SCD40L 
 
 
                 
                 
 
 
 
 
 
Structure of CD40-CD40L and regulation of its expression: 
           CD40 is a Type I transmembrane protein and a member of TNF super 
family(66,72). Its gene is located in chromosome 20(q12-13.2). CD40 exists as a 
dimer which trimerizes after binding of CD40L. It exists on cell surface as a 
constitutional trimer complex, which is crucial for its activation. CD40 has a 
cysteine rich (consisting of 20 residues) extracellular region. 
 
       CD40 protein consist of 4 cysteine rich domains, each domain is divided 
into two cysteine molecules(A1,B1,A2,B2).The CD40L is a Type II 
transmembrane protein with an external carboxy terminus and an intracellular 
amino terminus.        
      CD40 L gene: 
          A human sCD40L cDNA has been isolated by screening stimulated 
human blood T-cell libraries with the murine CD40L probe(73).  The cDNA for 
human sCD40L encodes a polypeptide of 261 amino acids which consists of a 
22 AA cytoplasmic domain, a 24AA transmembrane domain and a 215 AA 
extra cellular domain with five cysteines. 
         The gene for human sCD40L is located in the X chromosome at xq26.3-
xq27.1 position. 
       The human sCD40L gene consists of five exons and spans 12-13 kb of 
chromosomal DNA .The first exon codes for small portion of the extracellular 
region and whole of the intracellular transmembrane region. Extra cellular 
domain is coded by the exons II-IV . This sequence also includes 2000bp 
approximately of 5 promoter sequences. 
sCD40L mRNA has been detected in activated CD4+, CD8+, gamma 
delta T- cells. It has been detected in other cell types such as dentritic cells, 
monocytes basophils, mast cells eosinophils and B cells(74). 
 
CD40L protein: 
          Initial studies revealed a molecular mass of 39 kDa for CD40L, hence 
called gp39. But the molecular mass of CD40L on most cell types is 32-33 kDa 
which suggests that some post translational modification take place. 
         A single N-linked glycosylation site (human Asparagine 240) has been 
conserved in the extracellular region of human sCD40L. Comparison of human 
sCD40L (Swiss prot NO:P29965) and mouse sCD40L (Swiss prot NO:P27548) 
show that there is 78% AA identity between both sequences. There is 75% 
identity in the extracellular domain , 96% identity between the transmembrane 
region and 81% between the cytoplasmic domain(75). 
        sCD40L is produced as a type II transmembrane protein, it may be 
expressed on the cell surface. In addition to the 33 kDa form, the molecule is 
associated with two shorter versions of the protein of 31 and or /18 kDa.  
 
Regulation of sCD40L expression: 
        The expression of sCD40L on activated T-cells is transient and tightly 
regulated sCD40L expression can be seen on subpopulation of 
CD4+CD5+ROT cells, as early as 5-15 minutes after anti CD3 activation. 
       Expression occurs early (1-2 hours) after activation , is maximal after (6-8 
hours) and is followed by a gradual loss.  
  CD40-CD40L inter action leads to 
1) release of sCD40L which binds to CD40L 
2) receptor mediated endocytosis of CD40L and lysosomal degradation. 
  3) sCD40L is cleaved proteolytically. 
  4) down regulation of CD40L mRNA 
             Thrombin activation of human platelets resulted in CD40L surface 
expression within one minute. Increased serum levels of sCD40L has been also 
reported in various collagen diseases such as Systemic Lupus Erythematosus, 
Systemic Sclerosis and Rheumatoid Arthritis. Autoantibody to CD40L has 
been demonstrated in SLE(73). 
        A wide range of platelet activators such as thrombin and thrombin 
receptor agonists like phorbal myristate, collagen stimulate the platelets to 
express CD40L. Intra cellular calcium concentration and protein kinase C 
activation regulate CD40L expression. 
       Nitric oxide signaling also partly regulates the expression of CD40L by 
platelets. Inhibition of NO synthase in humans induces platelet activation 
which in turn cause CD40 adipocyte over expression and thereby cause 
atherogenesis. 
      Transient expression of CD40L gives the antigen activated T cell , a brief 
opportunity to deliver helper signals to interacting macrophages, B cells or 
dentritic cells.CD40L expression is upregulated by CD28, cytokines IL-12,IL-
15,IL-2, whereas CD40L expression is downregulated by IL-10,IL-4(76).  
 
                               
 
 
 
 
 
 
 
 
 
 
 
 
 
     AIMS AND OBJECTIVES 
 
1. To estimate Serum sCD40Llevel in patients with Acute Coronary 
Syndrome. 
2. To correlate the levels of Serum sCD40L with Serum CK-MB which is 
an effective marker of Acute Coronary Syndrome. 
3. To correlate the levels of Serum sCD40L with Lipid profile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                
 MATERIALS AND METHODS 
 
          The study was conducted at Thanjavur Medical College Hospital after 
getting the approval from the ethical committee. In the present study the age 
group of both study and control group ranged from 35-68 years , males and 
females were included and informed consent obtained from them. 
50 subjects (30 males and 20 females) who were admitted in ICCU of 
Thanjavur Medical College Hospital with Acute Coronary Syndrome and with 
clinical findings suggestive of STEMI (n=33),  NSTEMI ( n=4) and unstable 
angina ( n=13) were included in the study group. 50 sex and age matched , 
healthy individuals were taken as control groups. 
INCLUSION CRITERIA 
    1. Patients admitted with complaint of chest pain within 6 hours of onset, 
chest pain lasting >30 minutes. 
   2. Electrocardiographic findings showing abnormal ST-T wave changes ( ST 
segment elevation > 1mm in two or more contiguous chest leads or depression 
or deep symmetrical T wave inversion) . 
   3. Elevation of serum CK-MB levels more than the normal range .                                                                                                                              
EXCLUSION CRITERIA 
1.Anaemia 
2.Infection 
3. Malignant disease 
4 . Collagen disease  
   5.  Stroke 
           6. Cardiac disease other than coronary disease 
           7. Ballon angioplasty 
           8. Overt right or left ventricular failure 
           9. Thrombolytic treatment within three months of study  
BLOOD COLLECTION 
 Blood samples were collected by venepuncture with strict aseptic 
precaution as soon as the subjects got admitted as per the inclusion criteria. All 
the blood samples were centrifuged at 3000 rpm for 10 minutes and serum 
separated. 
One part of the serum sample was taken for analysis of CK-MB , 
Creatinine, and Urea. 
The remaining part of the serum sample was stored for analysis of 
soluble CD40L at -40ºC  
    12-14 hours fasting blood sample was also collected from all subjects 
during their hospital stay and analysis of total cholesterol, TGL, HDL-C, 
fasting blood sugar were done. 
 
 
 
 
 
 ANALYSIS OF BLOOD SAMPLES: 
   The serum sample collected above was used for the estimation of the 
following parameters. 
 
A) ESTIMATED PARAMETERS 
1. Serum sCD40L-              Enzyme Linked Immuno Sorbant Assay 
2  Serum.CK-MB –             Kinetic immuno inhibition method 
3.  FBG-                              Trinders method, end point, fixed time 
4. Blood Urea-                    Urease – GLDH method 
5. Serum Creatinine   -       Jaffes method, initial rate 
6. Serum TC     -                Cholesterol oxidase-PAP, end point 
7. Serum TGL  -                GPO-PAP method, end point 
8. Serum HDL-C  -            Phosphotungstic acid method, end point 
9. Serum LDH -                 Modified IFCC Method 
10. Serum AST-                DGKC Method, Kinetic 
 
B) CALCULATED PARAMETERS 
 
S. LDL-C and S. VLDL-C are calculated using Friedewald’s formula: 
VLDL-C = TGL/5 
LDL-C =   TC- [HDL+(TGL/5)] 
 
 HUMAN SERUM SOLUBLE CD 40 LIGAND ASSAY: 
PRINCIPLE OF THE ASSAY: 
This assay is an in vitro enzyme- linked immunosorbant assay for the 
quantitative  measurement of human CD40 in serum, plasma. This assay 
employs an antibody  specific for human CD40 coated on a 96 –well plate.  
Standards and samples are pipetted  into the wells and CD40 present in a 
sample is bound to the wells by the immobilized  antibody. The wells are 
washed and  biotinylated anti-human CD40 antibody is added. 
After washing away unbound biotinylated antibody , HRP-conjugated 
streptavidin is  pipetted into the wells . The wells are again washed , a TMB 
substrate solution is added to the wells and color develops in proportion to the 
amount of CD40 bound. The Stop  Solution changes the color from blue to 
yellow  and the intensity of the color is  measured at 450 nm. 
 
REAGENTS: 
1. CD40 Microplate (Item A): 96 wells (12 strips x 8 wells) coated with             
antihumanCD40 
2. Wash Buffer Concentrate (20 x) (Item B): 25 ml of 20 x concentrated 
solution. 
3. Standards (Item C): 2 vials , recombinant human CD40. 
4. Assay Diluent D (Item K) : 15 ml of 5x concentrated buffer. For 
Standard /Sample (Serum/plasma samples /cell culture medium/urine) 
diluent. 
5. Assay Diluent B (Item E): 15 ml of 5x concentrated buffer. For 
detection antibody and HRP –Streptavidin diluent. 
6. Detection Antibody CD40 (Item F): 2 vial of biotinylated anti-human 
CD40 (each vial is enough to assay half micropalte) 
7. HRP- Streptavidin concentrate (Item G): 8 µl 25,000x concentrated 
HRP-concentrated streptavidin. 
 
8. TMB One –Step Substrate Reagent (Item H): 12 ml of 3,3,5,5 
tetramethylbenzidine (TMB) in buffered solution. 
9. Stop Solution (Item I): 8 ml of 2 M sulfuric acid. 
 
STORAGE: 
1. The components of the kit are stored at 2-8º C. 
2. Standard (recombinant protein) should be stored at -20º C or -80º C 
after reconstitution. 
3. Opened Microplate Wells or reagents may be stored for upto 1 month  
at  2-8º C. 
 
 
 
 SAMPLE COLLECTION, SEPARATION, STORAGE: 
Serum: 
The blood samples were collected and centrifuged at 3000 rpm for 10 
minutes. 
Then serum samples were separated and stored at -20º C. 
 
 REAGENT PREPARATION: 
1. Bring all reagents and samples to room temperature (18-25º C) before 
use. 
2. Assay Diluent D (Item K) and Assay Diluent B (Item E) should be 
diluted 5-fold with deionized water or distilled water before use. 
 
3.  PREPARATION OF STANDARD: 
Briefly spin the vial of Item C. Add 400 µl 1x Assay Diluent D (Item K) 
into Item C  vial to prepare a100ng/ml standard solution. Dissolve the powder 
thoroughly by  a gentle mix. Add 180 µl CD40 standard from the vial of Item 
C,  into a tube with270µl 1xAssay Diluent D to prepare a 40,000 pg/ml 
standard solution. Pipette 400µl  1xAssay Diluent D into each tube .Use the 
stock standard solution to produce a  dilution series. Mix each tube thoroughly 
before the next transfer. Gently vortex to  mix. 1xAssay Diluent D serves as the 
zero standard (0 pg/ml) 
 
 
 STANDARD POINT             DILUTION SCD40 LIGAND    (ng/ml) 
S1 180µl standard+270µl 1xAssay Diluent D 40 .00 
S2 200µl S1 +400 µL 1x Assay Diluent D 13.33 
S3 
200µl S2 +400µl 1x 
Assay Diluent D 
 
4.44 
S4 200µl S3 + 400 µl 1x Assay Diluent D 1.48 
S5 200µl S4 +400µl 1xAssay Diluent D 0.493 
S6 200µl S5 + 400µl 1x Assay Diluent D 0.164 
S7 200µl S6 +400µl 1x Assay Diluent D 0.054 
S8 400µl 1x Assay Diluent D 0.0 
 
4. Wash concentrate (20x) (Item B) contains visible crystals , warm to room 
temperature and mix gently until dissolved .Dilute 20 ml of Wash Buffer 
Concentrate  into deionized or distilled water to yield 400 ml of 1x Wash 
Buffer (1:20). 
5. Briefly spin the Detection Antibody vial (Item F) before use. Add 100µl of 
1x  Assay Diluent B (Item E) into the vial to prepare a detection antibody 
concentrate.  Pipette up and down to mix gently .The detection antibody 
should be diluted 80 fold  with 1xAssay Diluent B . 
 6. Briefly spin the HRP-Streptavidin concentrate vial (Item G) and pipette up 
and  down to mix gently before use. Add 2µl of HRP-Streptavidin 
concentrate into a tube  with 198µl 1x Assay Diluent B to prepare a 100 fold 
diluted HRP-Streptavidin .Mix  through and then pipette 40µl of prepared 
100 –fold diluted solution into a tube  with10 ml 1x Assay Diluent B to 
prepare a final 25,000 fold diluted HRP Streptavidin  solution.    
 
ASSAY PROCEDURE: 
1. Bring all reagents and samples to room temperature (18-25º C) before 
use. It is  recommended that all standards and samples be run in 
duplicate. 
2. Add 100µl of each standard and sample into appropriate wells. Cover 
well and  incubate for 2.5 hours at room temperature .       
3. Discard the solution and wash 4 times with 1x Wash Solution . Wash by 
filling  each well with Wash Buffer (300µl) using a multi-channel 
Pipette. Complete removal  of liquid at each step is essential to good 
performance. After the last wash, remove  any remaining Wash Buffer 
by aspirating or decanting. Invert the plate and blot it  against clean 
paper towels.  
 4. Add 100µl of 1x prepared biotinylated antibody to each well. Incubate 
for 1 hour at room temperature with gentle shaking. 
5. Discard the solution and wash 4 times with 1xWash Solution (300µl) 
using a multi- channel Pipette .Invert the plate and blot it against clean 
paper towels. 
6. Add 100µl of prepared Streptavidin solution to each well .Incubate for 
45 minutes  at room temperature. 
7. Discard the solution and wash with 1x Wash solution (300µl) using a 
multi-channel  Pipette .Invert the plate and blot it against clean paper 
towels. 
8. Add 100µl of TMB One –Step Substrate Reagent (Item H) to each well. 
Incubate for 30 minutes at room temperature in the dark with gentle 
shaking. 
9. Add 50µl of Stop Solution (Item I) to each well. Read at 450 nm 
immediately. 
  
DATA ANALYSIS: 
The mean absorbance for each set of duplicate standards, controls, and 
samples were calculated and the average zero standard optical density was 
subtracted. The standard curve on log-log graph paper was plotted, with 
standard concentration on the x-axis and absorbance on the y-axis.  
   Plasma reference value- 1.57±0.78 ng/ml. 
 
 
 
  
ESTIMATION OF SERUM CREATINE KINASE-MB: 
Methodology: Kinetic immuno inhibition method 
Principle: 
This procedure involves measurement of CK activity in the presence of 
antibody to CK-M monomer. This antibody completely inhibits the activity of 
CK-MM and half of the activity of CK-MB while not affecting B subunit 
activity of CK-MB and CK-BB. Then the CK method is used to quantitatively 
determine CK-B activity. The CK-MB activity is obtained by multiplying the 
CK-B activity by 2. 
                                     
               Creatine phosphate + ADP                            Creatine + ATP 
                 Hexokinase 
              ATP + D-glucose                             Glucose-6-Phosphate + ADP 
                        G-6-PDH 
Glucose-6-Phosphate + NADP + H+                            6-Phospho gluconate + NADPH  
G-6-PDH – Glucose -6-phosphate dehydrogenase 
Sample: Unhemolysed serum used 
Reagents: 
Reagent 1  –  Buffer/enzymes 
Creatine Kinase 
Reagent 1A  –  Anti human polyclonal CKM antibody (goat) 
Reagent Reconstitution – Reagents were allowed to attain the room 
temperature. 3ml of Reagent 1A was added to 1 bottle of Reagent1. Mixed 
gently till it was completely dissolved and waited for 5 min. 
Procedure: 
 Test 
Reconstituted reagent 1ml 
Sample 50µl 
 
 
Mixed well and read immediately at wavelength of 340 nm. 
Reference values – Serum - 0 to25 IU/L 
 
ESTIMATION OF BLOOD GLUCOSE 
Method: Trinders method, end point/fixed time 
Principle: 
    Glucose in the sample is oxidized to yield gluconic acid and hydrogen 
peroxide in the presence of glucose oxidase. 
The enzyme peroxidase catalyses oxidative coupling of 4-amino 
antipyrine with phenol to yield a colored quinoneimine complex, with 
absorbance proportional to concentration of glucose in the sample.  
     Glucose + O2+ H2O                                     Gluconoic acid + H2O2 
     H2O2 + Phenol + 4AAP                                   Quinoimine dye + 2H2O2 
Glucose standard: 100 mg/dl 
Specimen : Fresh unhemolysed serum used. 
 
Assay procedure: 
Pipette into test 
tube labeled as Blank Standard Test 
Sample - - 10µl 
Standard - 10 µl - 
Enzyme reagent 1 ml 1 ml 1 ml 
Distilled water 10 µl - - 
 
Mixed well after each addition and incubated at 37º C for 5 minutes. The 
absorbance of the standard and the test were read against reagent blank at 
505 nm. 
 
CALCULATION: 
Glucose (mg/dl) = absorbance of test/ absorbance of standard X concentration 
of standard (100 mg/dl) 
Linearity upto 500 mg/dl by end point method. 
 NORMAL VALUES: 
Glucose fasting 65-110 mg/dl 
Glucose postprandial 90-130 mg/dl 
 
ESTIMATION OF BLOOD UREA: 
METHOD: Urease-GLDH method 
PRINCIPLE: 
                     Urea in the sample is hydrolyzed by urease to ammonia and 
carbon dioxide. The second reaction catalyzed by glutamate dehydrogenase 
(GLDH) converts ammonia and α-ketoglutarate to glutamate and water with the 
concurrent oxidation of reduced NADH to NAD. Two moles of NADH are 
oxidized for each mole of urea present. 
                Urea + H2O                         2NH4+ + CO2  
NH4+ + NADH + H+ + 2-Oxoglutarate                     Glutamate + NAD+  
The initial rate of decrease in absorbance at 340 nm is proportional to the urea 
concentration in the sample. 
 
 
Urease 
GLDH 
REAGENT COMPOSITION: 
Reagent 1: α-ketoglutaric acid 99.8 mmol/L, Urease 23.5 KU/L, GLDH 3.5 
KU/L,     Adenosine diphosphate 7.6 mmol/L, Sodium azide 0.2% 
Reagent 2: NADH 2.95 mmol/L, Sodium azide 0.1% 
 
REAGENT PREPARATION: 
Working reagent was prepared by mixing 4 parts of reagent 1 with one part of 
reagent 2. 
PROCEDURE: 
PIPETTE INTO 
TUBES BLANK STANDARD TEST 
Working Reagent 1000 µl 1000 µl 1000 µl 
Standard - 10 µl - 
Test - - 10 µl 
 
Mixed well and the absorbance was read after 30 seconds (A1) and 60 sec (A2) 
at 340 nm. 
CALCULATION: 
∆A = A2 – A1 
mg/dl) (50 standard ofion Concentratx 
  standard ofA 
 testofA 
 (mg/dl)  Urea
∆
∆
=
 
LINEARITY: The method is linear upto 200 mg/dl 
REFERENCE INTERVAL: 15-30 mg/dl 
 
ESTIMATION OF SERUM CREATININE: 
Method: Jaffes method, initial rate 
Methodology: Modified Jaffes reaction 
PRINCIPLE: 
 Creatinine present in the sample  reacts with picric acid in alkaline medium 
forming creatinine picrate(red colored complex) which is measured 
photometrically at 490 nm. 
Reagent composition; 
Reagent 1- picric acid reagent 
Reagent 2- sodium hydroxide 
Creatinine standard-2 mg/dl 
Reagent preparation: 
Equal volume of reagent 1 and 2 were mixed and allowed to wait for 15 min 
before use.  
Sample: Unhemolysed serum use 
 Assay procedure: 
Pipette into tubes marked Standard Test 
Working reagent 1000µl 1000µl 
Standard 100µl - 
Test - 100µl 
 
Mixed well and initial absorbance (A1) was read at 20 sec after mixing and 
final absorbance (A2) after 80 sec after mixing. 
CALCULATION: 
Delta A =A2-A1 
Creatinine (mg/dl) = delta A of the test /delta of the standard x concentration of 
the standard (mg/dl) 
Linearity – upto20 mg/dl 
ESTIMATION OF SERUM TOTAL CHOLESTEROL 
Method :  Cholesterol oxidase-PAP, endpoint 
Principle:   
 
1. Cholesterol ester +Water               Cholesterol + Fatty acid 
 
 Cholesterol esterase  
 
Cholesterol oxidase 
2. Cholesterol + Oxygen                       Cholest-4-en-3one + H2O2 
 
3. 2H2O2 + 4AAP+ Phenol                       Quinoneimine dye + 4H2O 
 4AAP- 4 amino antipyrine 
 Absorbance of quinoneimine formed is directly proportional to 
cholesterol concentration. 
 Cholesterol standard – 200mg/dl 
 Sample:  Unhemolysed serum  
 
REAGENT COMPOSITION: ready for use 
Goods buffer (PH-6.4) :  100mmol/L 
Cholesterol oxidase    :  >100U/L 
Cholesterol esterase     :  >200U/L 
Peroxidase                   :  >3000U/L 
4-Aminoantipyrine     : 0.3mmol/L 
Phenol                         :  5mmol/L 
 
 
 
Peroxidase 
ASSAY PROCEDURE: 
REAGENTS BLANK STANDARD TEST 
Working reagent 1000 µl 1000 µl 1000 µl 
Standard - 10 µl - 
Sample - - 10 µl  
Distilled water 10 µl  - - 
 
 Mixed well and incubated for 10 min at room temperature. The 
absorbance of the test and standard were read against reagent blank at 
wavelength of 505 nm. 
 
 
 
 
CALCULATION: 
(mg/dl) standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
 (mg/dl) lCholestero =
 
 
 
 REFERENCE RANGE: 
SERUM/PLASMA mg/dl 
2-12 months 60-190 
≥ 1 year 110-230 
Adults < 200 
 
Linearity-upto 700mg/dl 
Sensitivity-1mg/dl 
Interference: 
Hb upto 200mg/dl, ascorbate upto 12mg/dl, bilirubin upto 10mg/dl and 
Triglycerides upto 700 mg/dl do not interfere with the test. 
 
 
TRIGLYCERIDES: 
ESTIMATION OF SERUM TRIGLYCERIDES: 
Method: GPO-PAP method, endpoint 
Methodology: 
Colorimetric, enzymatic method with glycerol phosphate oxidase. 
This reagent is based on the method of Wako and the modifications by 
Mc Gowan et al.. and Fossati et al.. 
PRINCIPLE: 
Triglycerides + H2O                    Glycerol + free fatty acids 
Glycerol + ATP                     Glycerol 3 phosphate + ADP 
 
Glycerol 3 phosphate + O2                      DAP + H2O2 
 
H2O2 + 4AAP + 3,5-DHBS                             Quinoneimine dye+2H2O 
ATP- Adenosine Tri Phosphate 
4AAP- 4Amino Anti Pyrine 
DHBS-3,5 Dichloro-2Hydroxy Benzene Sulfonate 
The intensity of Quinoneimine dye formed is proportional to the 
triglyceride concentration in the sample when measured at 505 nm (500-
540nm). 
Triglycerides standard concentration- 200mg/dl 
 
 
Lipoprotein lipase 
Glycerol kinase 
Mg
2+
 
Glycerol Phosphate Oxidase 
Peroxidase 
REAGENT COMPOSITION 
Reagent 1( Enzymes / Chromogen) 
 
 
 
REAGENT 2 
Pipes buffer, PH-7.0 :  40mmol/L 
DHBS:0.2mmol/L 
Magnesium salt: 2.5mmol/L 
 
Working reagent preparation: 
The working reagent was prepared by mixing 4 parts of R1 with 1 part 
of R2, stable for 90 days at 2-8 ◦C. 
Sample:  Unhemolysed serum collected after 12 hrs of fasting. 
Lipoprotein lipase 4000 U/L 
4-Amino antipyrine 0.4 mmol/L 
ATP 2mmol/L 
Glycerol kinase 1500 U/L 
Peroxidase 2200 U/L 
Glycerol Phosphate Oxidase 4000 U/L 
                                                                                                                                                             
ASSAY PROCEDURE: 
Reagents Blank Standard Test 
Working reagent 1000µl 1000 µl 1000 µl 
Standard - 10 µl - 
Sample - - 10 µl  
Distilled water 10 µl  - - 
 
Mixed well and incubated for 10min. 
Absorbance were read at 505nm for standard and sample against reagent 
blank. 
 
Calculation: 
(mg/dl) standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
  (mg/dl) desTriglyceri =
 
 
 
 
Reference values: 
 
 
 
Linearity – upto 1000mg/dl 
Sensitivity- 2mg/dl 
Specificity/interference: 
Hb upto 300mg/dl,  ascorbate  upto 3mg/dl, bilirubin upto 20mg/dl 
 
 ESTIMATION OF SERUM HDL CHOLESTEROL  
Phosphotungstic acid method, endpoint 
Principle: 
Chylomicrons, LDL and VLDL are precipitated from serum/phospho 
tungstate in the presence of divalent cations such as Magnesium. The HDL 
cholesterol reminds unaffected in the supernatant and is estimated using 
cholesterol reagent. 
  
Serum/plasma                                     HDL  +  (LDL + VLDL+ Chylomicrons)
               (supernatant)            (Precipitate) 
Serum/plasma 37◦C 
Normal fasting level 25-160mg/dl 
Phosphotungstate 
  Mg
2+ 
 
 Reagent composition: 
Reagent1: precipitating reagent 
Phosphotungstic acid 2.4mmol/l 
Magnesium chloride 40mmol/l 
 
HDL cholesterol standard – 25mg/dl 
SAMPLE: Unhemolysed serum used 
 
PRECIPITATION: 
Precipitation of LDL, VLDL  and Chylomicrons done as follows: 
           Pipette  Volume 
Test 250µl 
Precipitating 
reagent 
500 µl 
 
Mixed well and the reaction mixture was allowed to stand for 10 min at 
room temperature, centrifuged at 4000 rpm for 10 min and obtain a clear 
supernatant. The supernatant was used to determine the concentration of HDL 
cholesterol in the sample. 
ASSAY PROCEDURE: 
 
 
 
Mixed well and incubated for 10 min at room temperature. 
The absorbance of the standard and the test samples were read at 505 nm 
against reagent blank. 
 
 
 
Calculation: 
factordilution   x (mg/dl)  standard ofion Concentratx 
  standard of Absorbance
 testof Absorbance
  (mg/dl) lcholestero HDL =  
       = 
  standard of Absorbance
 testof Absorbance
  x 25 x 3 
Reagents Blank Standard Test 
Cholesterol working 
reagent 1000µl 1000 µl 1000µl 
Distilled water 50 µl - - 
HDL standard - 50 µl - 
Supernatant - - 50 µl 
   = 
  standard of Absorbance
 testof Absorbance
 x 75 
Linearity - upto 125mg/dl 
 
Normal values:  
Males     - 30 to  65mg/dl 
Females – 35 to 80mg/dl 
Interference: 
High triglyceride concentration above 300 mg/dl cause interference with 
the assay. 
Bilirubin and ascorbate at high concentrations interfere with 
precipitation 
 
 
FRIEDEWALD’S EQUATION FOR CALCULATION OF SERUM LDL           
CHOLESTEROL 
TGL/5 = VLDL, if TGL is less than 400mg/dl 
LDL-C = Total cholesterol – (HDL -C+ VLDL-C) 
 
ESTIMATION OF SERUM LACTATE DEHYDROGENASE (LAH-P) 
                                    DGKC, METHOD, KINETIC 
METHODOLOGY 
Method of Henry et.al2. 
PRINCIPLE 
    When pyruvate is converted to Lactate in the presence of NADH , oxidation 
of NADH to NAD is measured at 340 nm and the decrease in absorbance is 
directly propotional to LDH activity 
 
 
 
 
REAGENT COMPOSITION (When reconstituted as directed) 
REAGENT 1:  LDH Reagent 
Pyruvic acid 0.60 mmol/L 
NADH(Yeast) 0.23 mmol/L 
Phosphate buffer pH7.5 
  
Also contains non-reactive filters and stabilizers. 
 
 
 
 
 REAGENT RECONSTITUTION 
The reagent and the Aqua-4 (supplied in the kit) is allowed to attain 
room temperature, the amount of Aqua-4 indicated on the label is added to 
contents of each vial, swirled to dissolve and should not be shaken vigorously. 
 
ASSAY PROCEDURE 
Pipette Volumes 
Working Reagent 1000µl 
Test 20 µl 
 
Mixed well and aspirated. 
 
CALCULATION 
The absorbance change/min (∆ A/Min.) for every reading is calculated 
and the mean value is found out. 
IU/L      =
 ∆	.

.   
 
Where: 
T.V.                 =  Total reaction Volume in µl   
S.V.                 =  Sample Volume in  µl   
Absorptivity    = millimolar absorptivity of NADH at 340 nm 
                        = 6.22 
                P      = cuvette light path (cm) 
                       =1cm 
Activity of LDH-P at 370 C (IU/L) = (  A340 /min)x Factor(8199) 
LINEARITY: 
   Upto 1000IU/L . For higher values it is recommended to dilute the 
samples with normal saline and repeat the assay . Multiply the final results with 
the dilution factor. 
NORMAL VALUES: 
           Serum LDH level =  180-360 U/L . 
 
 
 
 
 
ESTIMATION OF SERUM ASPARTATE AMINOTRANSFERASE 
Methodology: Modified IFCC Method 
Principle: 
         The transfer of amino group from L- Aspartate to α- ketoglutarate to yield 
oxaloacetate and L – Glutamate is catalyzed by AST. When Oxaloacetate 
undergoes reduction there is simultaneous oxidation of NADH to NAD in  the 
presence of MDH. 
        The decrease in the rate of absorbance at 340nm is directly proportional to 
the AST activity. Interference from endogenous pyruvate which is normally 
present in serum is prevented by the addition of LDH. 
                                                                       AST 
 L-Aspartate +α –ketoglutarate                       Oxaloacetate +L-glutamate 
           
                                                                 MDH   
  Oxaloacetate +NADH +H                           Malate +NAD 
 
 
REAGENT COMPOSITION  
R1: 
Tris Buffer (pH 7.8)  – 20 mmol/L 
L-Aspartate              - 230mmol/L 
LDH                       - > 33.3µkat/L 
2- Oxoglutarate      - 13.21 mmol/L 
MDH                    - 3.333µkat/L 
Also contains Non –reactive fillers and stabilizers. 
R2: 
NADH                   - 1.51MMOL/L 
 
REAGENT PREPARATION:  
Prepare the working reagent by mixing 4 parts of R1 with 1part of R2 per assay 
tube. 
 
ASSAY PROCEDURE: 
Pipette Volumes 
Working reagent 500µl 
Test 25 µl 
 
 
CALCULATION: 
AST  ACTIVITY (IU/L)   =  D A/min. x Factor(3376) 
 
LIMITATIONS: 
1.Sample with values above 1600 IU/L should be diluted 1:1 with saline, 
reassayed and the results multiplied by two. 
2. Patients with severe vitamin B6 deficiency could have a decreased recovery 
of AST , presumably due to a lack of pyridoxal phosphate. 
 
LINEARITY:  
AST reagent is linear upto 1600 U/L . For values above the linearity 
limit dilute with saline and reassay. Multiply by the dilution factor to obtain the 
end result. 
 
EXPECTED VALUES: 
                           Adult Male:  <35  U/L 
                          Adult Female: <31  U/L  
        
                                      STATISTICAL ANALYSIS 
 
• Student T –test and Chi- square test were employed for the statistical 
analysis of data. 
• The data were expressed in terms of mean and standard deviation. 
• 
‘P’ value less than 0.05 was taken as significant value. 
• Correlation between the measured parameters was assessed using 
Pearson’s coefficient of correlation.        
   
 
 
 
 
 
 
 
 
 
 
    
                                                         MASTER CHART 1 - CONTROL GROUP 
       
S.N
O 
AG
E 
SE
X 
WEI
GHT 
(kg) 
HEIG
HT 
(m) 
BM
I 
SBP 
mm
Hg 
DBP 
mm
Hg 
SCD
40L 
ng/
ml 
CKM
B 
U/L 
FBG 
mg/dl 
UR
EA 
mg
/dl 
CR
EA
T 
mg
/dl 
TC 
mg/
dl 
TGL 
mg/
dl 
HD
L 
mg
/dl 
LDL 
mg/
dl 
VLD
L 
mg/
dl 
LDH 
U/L 
AS
T 
U/
L 
1 65 F 64 1.6 25 122 82 1.26 7 96 29 0.5 193 100 43 130 20 120 12 
2 48 F 50 1.5 22 110 70 1.24 14 93 28 0.9 188 115 25 140 23 140 14 
3 62 F 70 1.65 26 100 80 1.34 12 91 32 0.8 179 160 31 116 32 136 19 
4 67 F 60 1.53 26 120 80 1.39 10 90 18 0.8 159 130 52 81 26 145 20 
5 44 F 65 1.65 24 110 80 1.44 7 98 22 0.7 158 133 39 92 27 155 14 
6 57 F 55 1.48 25 100 82 1.41 16 92 36 0.6 183 138 51 114 28 180 15 
7 61 F 60 1.48 27 122 70 1.36 17 98 20 0.7 165 145 49 87 29 135 18 
8 54 F 63 1.45 30 123 72 1.52 20 96 24 0.8 195 135 50 118 27 125 12 
9 63 F 60 1.55 25 130 76 1.5 18 89 28 0.5 145 120 43 78 24 140 11 
10 55 F 62 1.54 26 100 80 1.54 20 90 30 0.6 172 113 41 108 23 128 13 
11 46 F 55 1.5 24 120 80 1.28 16 92 20 0.7 171 122 40 107 24 149 14 
12 37 F 58 1.52 25 114 74 1.32 12 94 28 0.9 186 126 49 112 25 138 19 
13 50 F 65 1.55 27 110 70 1.4 10 98 32 0.8 156 130 32 98 26 126 18 
14 65 F 55 1.6 21 130 80 1.51 14 86 18 0.5 173 145 45 99 29 142 16 
15 45 F 60 1.52 26 110 80 1.56 12 92 22 0.6 171 122 40 107 24 138 12 
16 60 F 60 1.53 26 126 84 1.25 13 96 24 0.7 141 115 43 75 23 130 17 
17 52 F 58 1.52 25 124 80 1.37 17 90 22 0.5 176 170 40 102 34 145 13 
18 40 F 55 1.48 25 110 80 1.64 15 96 32 0.8 179 160 31 116 32 138 14 
19 55 F 55 1.6 21 128 80 1.34 20 88 30 0.6 127 150 25 72 30 128 15 
20 45 F 72 1.67 26 122 80 1.26 22 98 20 0.7 158 133 39 92 27 152 13 
21 45 M 65 1.65 24 126 82 1.57 16 86 22 0.8 178 141 24 126 28 142 18 
22 47 M 60 1.67 22 120 80 1.55 11 84 30 0.7 138 116 40 75 23 136 12 
23 57 M 70 1.7 24 112 74 1.35 16 90 28 0.7 176 115 52 101 23 148 11 
24 68 M 75 1.6 29 130 80 1.34 17 80 26 0.6 188 98 53 115 20 127 18 
25 39 M 70 1.6 27 120 80 1.27 12 98 24 0.8 190 111 33 135 22 136 19 
26 44 M 70 1.68 25 128 74 1.37 14 90 26 0.8 190 111 35 133 22 139 10 
27 62 M 80 1.7 28 110 70 1.39 14 102 22 0.7 173 145 45 99 29 140 17 
28 58 M 69 1.65 25 120 80 1.61 16 104 20 0.6 175 100 42 113 20 137 13 
29 48 M 75 1.68 27 116 84 1.3 10 98 30 0.5 154 155 49 74 31 143 18 
30 38 M 75 1.72 25 110 72 1.4 8 84 34 0.9 167 141 47 92 28 123 12 
31 47 M 72 1.69 25 110 70 1.66 16 96 24 0.7 150 86 35 97 18 131 19 
32 53 M 70 1.65 26 122 82 1.58 14 102 28 0.7 152 126 60 67 25 122 11 
33 64 M 69 1.6 27 110 80 1.49 12 92 22 0.8 160 140 66 66 28 136 15 
34 44 M 70 1.67 25 126 80 1.27 10 82 32 0.5 186 138 52 106 28 149 12 
35 40 M 75 1.71 26 120 82 1.59 14 106 26 0.7 145 72 59 72 14 138 18 
36 66 M 64 1.6 25 126 84 1.67 16 106 30 0.6 150 86 45 87 18 134 14 
37 37 M 74 1.68 26 110 80 1.22 11 104 24 0.9 173 97 24 130 19 152 19 
38 42 M 70 1.65 26 114 78 1.57 17 102 20 0.8 194 114 42 130 23 129 13 
39 55 M 75 1.68 27 130 80 1.48 22 86 30 0.5 159 65 38 108 13 125 18 
40 65 M 74 1.69 26 110 70 1.63 16 90 24 0.7 171 122 40 107 24 149 16 
41 41 M 67 1.67 24 116 84 1.38 8 104 22 0.7 142 132 32 74 26 152 10 
42 51 M 70 1.68 25 120 80 1.23 10 84 30 0.8 180 127 30 125 25 162 12 
43 43 M 67 1.67 24 110 70 1.3 5 98 32 0.6 200 128 58 120 22 139 18 
44 62 M 71 1.7 25 120 80 1.63 8 102 28 0.6 171 165 45 93 33 147 17 
45 59 M 72 1.67 26 120 80 1.4 6 82 24 0.8 148 126 51 72 25 130 13 
46 69 M 80 1.7 28 126 82 1.3 15 102 20 0.6 145 72 59 72 14 129 17 
47 43 M 65 1.72 22 120 80 1.33 12 92 22 0.6 138 140 52 58 28 157 15 
48 52 M 72 1.69 25 118 76 1.69 10 104 26 0.5 172 126 49 98 25 135 11 
49 55 M 68 1.62 26 120 80 1.49 14 98 30 0.7 161 155 46 84 31 141 19 
50 46 M 74 1.68 26 110 70 1.25 12 86 20 0.6 148 126 51 72 25 132 17 
 
  
 
 
                     
 
                     
                                                                                                   MASTER CHART 2 - STUDY GROUP 
  
                     
S.NO AGE SEX 
Wt 
(Kg) 
Ht 
(m) BMI 
SBP 
(mmHg) 
DBP 
(mmHg) 
DURATION 
(Hours) 
SCD40L 
(ng/ml) 
CK-
MB 
(U/L) 
FBG 
(mg/dl) 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
TC 
(mg/dl) 
TGL 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDH 
(U/L) 
AST 
(U/L) 
1 57 F 55 1.5 24.44 100 70 6 3.904 48 86 24 0.8 242 150 31 181 30 134 10 
2 55 F 64 1.56 26.29 150 100 4 3.812 46 98 20 0.7 240 152 33 177 30 191 22 
3 60 F 60 1.55 24.97 110 80 6 4.739 52 108 32 0.6 280 186 32 211 37 142 12 
4 55 F 65 1.52 28.13 100 80 4 3.944 48 118 28 0.7 243 168 34 176 33 149 15 
5 58 F 56 1.55 23.3 140 100 6 7.259 60 98 26 0.8 278 240 38 200 40 192 24 
6 55 F 60 1.53 25.63 110 70 4 3.386 46 220 18 0.7 287 198 36 217 34 136 18 
7 39 F 75 1.6 29.29 120 80 3 3.234 42 104 22 0.8 288 180 34 218 36 121 13 
8 46 F 73 1.65 26.81 100 80 6 4.394 54 98 34 0.8 285 172 32 219 34 140 16 
9 65 F 74 1.72 25.01 110 70 4 1.581 24 210 26 0.6 198 122 40 134 24 120 13 
10 55 F 64 1.68 22.67 160 100 3 1.376 21 96 30 0.7 197 216 41 113 43 191 26 
11 56 F 70 1.64 26.02 170 110 3 1.641 22 90 28 0.8 196 200 40 116 40 188 23 
12 75 F 72 1.67 25.81 90 70 2 1.491 20 96 22 0.8 195 114 43 130 22 112 11 
13 65 F 60 1.5 26.66 100 80 6 7.844 61 114 26 0.8 360 256 32 277 51 128 15 
14 70 F 72 1.5 32 110 70 6 1.396 23 92 36 0.6 197 106 41 135 21 139 16 
15 42 F 64 1.68 22.67 100 80 4 3.256 43 108 28 0.7 285 162 33 220 32 128 19 
16 57 F 55 1.6 21.48 140 90 4 3.434 41 98 22 0.6 288 167 38 217 33 177 22 
17 45 F 80 1.65 29.48 100 80 4 4.364 52 84 20 0.7 295 178 32 228 35 142 13 
18 68 F 60 1.53 25.63 110 80 6 5.709 54 176 18 0.6 285 189 32 215 38 139 12 
19 56 F 65 1.48 29.67 170 110 6 7.934 62 94 24 0.7 234 243 33 153 48 176 25 
20 60 F 56 1.55 23.3 120 80 5 8.099 64 112 20 0.8 249 276 34 160 55 122 18 
21 42 M 55 1.72 18.59 140 90 6 4.969 46 92 22 0.7 288 202 30 208 50 172 24 
22 55 M 70 1.64 26.02 110 80 4 3.104 40 104 30 0.6 289 156 33 225 31 154 19 
23 50 M 83 1.67 29.76 110 70 6 3.554 42 210 26 0.7 290 165 32 225 33 137 13 
24 48 M 75 1.6 29.29 100 70 3 3.506 45 108 18 0.8 298 176 34 229 35 129 11 
25 63 M 68 1.62 25.91 152 94 3 1.506 22 98 20 0.7 192 132 42 124 26 164 22 
26 45 M 86 1.64 31.97 180 110 4 5.939 68 88 24 0.8 287 276 30 202 55 190 26 
27 66 M 62 1.64 23.05 120 80 6 6.344 96 92 28 0.7 289 266 31 205 53 127 16 
28 65 M 64 1.6 25 110 70 4 7.634 76 86 32 0.6 310 265 34 223 53 134 18 
29 65 M 55 1.52 23.8 100 80 5 5.055 67 94 24 0.8 288 187 33 218 37 151 14 
30 54 M 62 1.68 21.96 110 90 6 5.594 66 78 26 0.7 285 183 32 217 36 122 12 
31 50 M 61 155 25.39 120 80 3 1.661 14 96 34 0.7 188 125 41 122 25 147 19 
32 45 M 76 1.72 25.68 144 96 4 4.424 67 102 28 0.8 285 210 30 213 42 191 24 
33 53 M 73 1.67 26.17 110 80 6 4.436 68 188 18 0.6 260 232 31 183 46 140 15 
34 50 M 65 1.67 23.3 120 80 3 5.369 66 90 20 0.8 275 190 31 206 38 139 19 
35 67 M 64 1.65 23.5 110 70 6 8.009 84 120 22 0.8 345 199 30 275 40 141 13 
36 56 M 62 1.7 21.45 100 80 5 6.449 98 118 28 0.6 289 186 35 217 37 153 14 
37 46 M 65 1.6 25.39 110 80 3 1.536 18 92 32 0.6 190 145 40 121 29 135 15 
38 50 M 67 1.65 24.6 90 70 4 4.484 70 104 24 0.6 278 184 36 205 37 122 18 
39 67 M 62 1.7 21.45 120 80 6 4.184 65 84 26 0.7 245 178 32 178 35 149 13 
40 45 M 64 1.64 23.79 100 70 4 5.414 84 78 32 0.6 276 198 33 203 40 153 15 
41 35 M 76 1.72 25.68 110 70 4 3.134 80 192 28 0.7 269 154 30 208 31 142 10 
42 47 M 65 1.7 22.49 150 90 3 1.396 18 94 20 0.7 192 240 44 100 48 192 23 
43 70 M 75 1.68 26.57 110 70 5 5.144 80 108 22 0.5 286 145 30 227 29 138 13 
44 55 M 70 1.64 26.02 150 100 4 4.319 68 118 24 0.7 248 232 33 169 46 182 26 
45 40 M 55 1.72 18.59 120 80 6 4.491 70 116 30 0.6 256 101 31 205 20 146 16 
46 65 M 65 1.6 25.39 110 80 3 6.599 105 96 24 0.8 259 156 32 194 33 139 14 
47 68 M 75 1.69 26.57 90 70 4 4.551 72 88 26 0.6 251 189 31 182 38 152 18 
48 63 M 77 1.7 26.64 110 70 5 4.799 75 76 22 0.8 259 190 33 188 38 145 13 
49 48 M 75 1.72 25.35 110 80 4 4.544 73 92 30 0.7 257 136 32 198 27 150 17 
50 66 M 70 1.64 26.02 110 90 6 4.934 78 104 24 0.6 260 179 33 191 36 140 19 
                 
TABLE 1: DESCRIPTIVE STATISTICS OF CONTROL AND STUDY 
SL.NO VARIABLES 
Control(n=50) Study(n=50) 
Min. Max. Mean S.D Min. Max. Mean S.D 
1 AGE(Yrs) 37 69 52.22 9.412 35 75 55.56 9.52 
2 Wt(Kg) 50 80 66.60 7.191 55 86 66.84 7.75 
3 Ht (mt) 1.45 1.72 1.61 0.07 1.48 1.72 1.6270 0.07 
4 BMI 21.48 29.96 25.34 1.72 18.59 32.00 25.29 2.83 
5 SBP (mm Hg) 100 130 117.62 8.002 90 180 118.72 22.18 
6 DBP (mmHg) 70 84 78.08 4.462 70 110 82.00 11.56 
7 S.sCD40Lng/ml 1.216 1.691 1.42 .139 1.37 8.09 4.39 1.90 
8 S.CK-MB U/L 5 22 13.48 4.04 14 105 56.08 22.58 
9 FBG mg/dl 80 106 93.94 6.97 76 220 110.12 35.34 
10 B.UREA mg/dl 18 36 25.82 4.60 18 36 25.36 4.65 
11 S.CREA mg/dl .5 .9 .684 0.12 .5 .8 .698 .084 
12 S.TC mg/dl 127 200 166.98 17.75 188 360 262.12 39.72 
13 S.TGL mg/dl 65 170 124.76 23.67 101 276 185.04 43.41 
14 S.HDL-C mg/dl 24 66 43.24 9.90 30 44 34.16 3.88 
15 S.LDL-C mg/dl 58 140 98.90 21.36 100 277 191.16 40.13 
16 S.VLDL-C mg/dl 13 34 24.86 4.75 20 55 36.80 8.75 
17 S.LDH U/L 120 180 139.00 11.32 112 192 148.86 22.37 
18 S.AST U/L 10 20 15.02 2.93 10 26 17.04 4.62 
                TABLE 2:  AGE  AND  SEX  DISTRIBUTION  IN  CONTROL AND  
                                                        STUDY  GROUPS 
 
 
SL.NO Age 
Control 
Statistical 
inference 
Study 
Statistical 
inference 
Male 
(n=30) 
Female 
(n=20) 
Male 
(n=30) 
Female 
(n=20) 
1 Below 40yrs 4 2 
X
2
=.521 
Df=3 
.914>0.05 
Not Significant 
2 1 
X
2
=8.576 
Df=3 
.035<0.05 
Significant 
2 41 to 50yrs 11 6 12 3 
3 51 to 60yrs 8 6 5 11 
4 
61yrs & 
above 
7 6 11 5 
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                  TABLE 3:   MEAN S. sCD40L  LEVELS IN CONTROL AND  
                                                     STUDY GROUPS 
 
 
S.sCD40L ng/ml MEAN S.D 
STATISTICAL 
INFERENCE 
Control  (n=50) 1.42250 0.139578 
T=-11.024 
P<0.001 Significant 
Study  (n=50) 4.39758 1.903162 
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                                                                                                                                                                                                                     TABLE 4: 
STATISTICAL ANALYSIS OF LIPID PARAMETERS BETWEEN CONTROL AND STUDY GROUPS 
 
                  SLNO        VARIABLES                  MEAN                        S.D  
STATISTICAL INFERENCE 
 
1. S.TC mg/dl    
T=-15.461 
P < 0.001 
Significant 
Control (n=50) 166.98 17.757 
Study (n=50) 262.12 39.723 
2. S.TGL mg/dl    
T=-8.620 
P < 0.001 
Significant 
Control (n=50) 124.76 23.671 
Study (n=50) 185.04 43.413 
3. S.HDL-C mg/dl    
T=6.035 
P < 0.001 
Significant 
Control (n=50) 43.24 9.905 
Study (n=50) 34.16 3.883 
4. S.LDL-C mg/dl    
T=-14.349 
P < 0.001 
Significant 
Control (n=50) 98.90 21.367 
Study (n=50) 191.16 40.132 
5. S.VLDL-C mg/dl    
T=-8.479 
P < 0.001 
Significant 
Control (n=50) 24.86 4.751 
Study (n=50) 36.80 8.751 
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TABLE 5: MEAN S. CK-MB VALUES IN CONTROL AND STUDY GROUPS 
 
 
SL.NO S.CK-MB U/L MEAN S.D 
STATISTICAL 
INFERENCE 
1.. Control(n=50) 13.48 4.047 
T=-13.129  
P<0.05 Significant 
2. Study (n=50) 56.08 22.584 
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  TABLE 6: MEAN LEVEL OF S. sCD40L LEVEL IN MALE CONTROL AND 
                                                        STUDY GROUP 
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S.sCD40L ng/ml Mean S.D Statistical inference 
Control(n=30) 1.442 0.151 T=-10.209 
P<0.05Significant Study(n=30) 4.569 1.670 
TBLE 7: MEAN S. sCD40L LEVEL IN FEMALE CONTROL AND STUDY    GROUP 
 
  
 
S.sCD40L ng/ml 
 
Mean 
 
S.D 
 
Statistical inference 
Control(n=20) 1.392 0.117 T=-5.507 
P<0.05 Significant Study(n=20) 4.139 2.227 
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TABLE 8 –STATISTICAL ANALYSIS OF S. sCD40L, S.CK-MB AND LIPID PARAMETERS IN MALE CONTROL AND 
STUDY GROUP 
SL.NO VARIABLES MEAN S.D STATISTICAL INFERENCE 
1. S.sCD40L ng/ml    
 Control (n=30) 1.44233 .151316 T=-10.209 
P < 0.001 
Significant 
 Study (n=30) 4.56940 1.670877 
2. S.CK-MB U/L    
 Control (n=30) 12.73 3.759 T=-11.752 
P < 0.01 
Significant 
 Study (n=30) 64.03 23.611 
3. S.TC mg/dl    
 Control (n=30) 165.80 17.924 T=-13.550 
P < 0.001 
Significant 
 Study (n=30) 266.13 36.380 
4. S.TGL mg/dl    
 Control (n=30) 119.20 25.656 T=-7.364 
P < 0..001 
Significant 
 Study (n=30) 185.90 42.463 
5. S.HDL-C mg/dl    
 Control (n=30) 45.13 10.641 T=5.746 
P < 0.001 
Significant 
 Study (n=30) 33.30 3.743 
6. S.LDL-C mg/dl    
 Control (n=30) 96.70 23.272 T=-12.322 
P<0.001 
Significant 
 Study (n=30) 195.37 37.175 
7. S.VLDL-C mg/dl    
 Control (n=30) 23.67 5.101 T=-7.459 
P<0.001 
Significant 
 Study (n=30) 37.47 8.756 
 
      TABLE 9 –STATISTICAL ANALYSIS OF S. sCD40L, S.CK-MB AND   LIPID  
                  PARAMETERS IN FEMALE CONTROL AND STUDY GROUP 
 
SL.NO VARIABLES  MEAN S.D STATISTICAL INFERENCE 
1. S.sCD40L ng/ml    
 Control (n=20) 1.39275 .117230 T=-5.507 
P < 0.001 
Significant  
 Study (n=20) 4.13985 2.227838 
2. S.CK-MB U/L    
 Control (n=20) 14.60 4.297 T=-8.653 
P < 0.01 
Significant  
 Study (n=20) 44.15 14.655 
3. S.TC mg/dl    
 Control (n=20) 168.75 17.814 T=-8.140 
P < 0.001 
Significant  
 Study (n=20) 256.10 44.562 
4. S.TGL mg/dl    
 Control (n=20) 133.10 17.841 T=-4.601 
P < 0.001 
Significant  
 Study (n=20) 183.75 45.884 
5. S.HDL-C mg/dl    
 Control (n=20) 40.40 8.127 T=2.465 
P<0.05 
Significant  
 Study (n=20) 35.45 3.818 
6. S.LDL-C mg/dl    
 Control (n=20) 102.20 18.211 T=-7.697 
P<0.001 
Significant  
 Study (n=20) 184.85 44.434 
7. S.VLDL-C mg/dl    
 Control (n=20) 26.65 3.588 T=-4.276 
P<0.001 
Significant  
 Study (n=20) 35.80 8.871 
 
                          TABLE 10: STATISTICAL ANALYSIS OF S. sCD40L, S.CK-MB, 
        LIPID PARAMETERSAND S.LDH, S.AST  IN CONTROL AND STUDY GROUP  
                                                      LESSTHAN 40YEARS 
 VARIABLES MEAN S.D STATISTICAL INFERENCE 
1. S.sCD40L ng/ml    
 Control (n=6) 1.40350 .174062 
T=-7.286 
P<0.001 
Significant  Study (n=3) 3.61967 .756252 
2. S.CK-MB U/L    
 Control (n=6) 12.00 2.449 
T=-6.853 
P < 0.01 
Significant  Study (n=3) 64.00 19.698 
3. S.TC mg/dl    
 Control (n=6) 173.33 16.207 
T=-8.539 
P<0.001 
Significant  Study (n=3) 271.00 16.093 
4. S.TGL mg/dl    
 Control (n=6) 117.83 31.505 
T=-1.122 
P>0.05 
Not Significant  Study (n=3) 145.00 40.262 
5. S.HDL-C mg/dl    
 Control (n=6) 40.50 13.233 
T=1.112 
P>0.05 
Not Significant  Study (n=3) 31.67 2.082 
6. S.LDL –C mg/dl    
 Control (n=6) 109.50 23.797 
T=-6.977 
P < 0.001 
Significant  Study (n=3) 210.33 6.807 
7. S.VLDL-C mg/dl    
 Control (n=6) 23.33 6.439 
T=-1.148 
P>0.05 
Not Significant  Study (n=3) 29.00 8.185 
8. S.LDH  U/L    
 Control (n=6) 137.50 9.203 
T=.156 
P>0.05 
Not Significant  Study (n=3) 136.33 13.429 
9. S.AST U/L    
 Control (n=6) 16.83 3.061 
T=1.781 
P>0.05 
Not Significant 
 Study (n=3) 13.00 3.000 
           
 
 
TABLE 11: STATISTICAL ANALYSIS OF S. sCD40L, S.CK-MB, LIPID PARAMETERS AND S.LDH, S.AST  IN 41-
50 YEARS OF AGE IN CONTROL AND 
STUDY GROUP 
SL.NO VARIABLES MEAN S.D STATISTICAL INFERENCE 
1. S.sCD40L mg/dl    
 Control (n=17) 1.39306 .138689 T=-7.244 
P < 0.001 
Significant  
 Study (n=15) 3.92067 1.434151 
2. S.CK-MB U/L    
 Control (n=17) 12.47 4.185 T=-7.191 
P < 0.01 
Significant  
 Study (n=15) 50.67 21.490 
3. S.TC mg/dl    
 Control (n=17) 165.88 20.448 T=-8.986 
P<0.001 
Significant  
 Study (n=15) 264.60 39.787 
4. S.TGL mg/dl    
 Control (n=17) 126.00 15.374 T=-5.664 
P<0.001 
Significant  
 Study (n=15) 183.93 38.939 
5. S.HDL-C mg/dl    
 Control (n=17) 40.29 9.610 T=2.332 
P<0.05 
Significant  
 Study (n=15) 34.00 4.342 
6. S.LDL-C mg/dl    
 Control (n=17) 100.06 24.322 T=-7.767 
P<0.001 
Significant  
 Study (n=15) 193.27 42.230 
7. S.VLDL –C mg/dl    
 Control (n=17) 25.00 3.102 T=-5.581 
P<0.001 
Significant  
 Study (n=15) 37.33 8.508 
8. S.LDH U/L    
 Control (n=17) 141.71 9.393 T=-1.509 
P>0.05 
Not Significant  
 Study (n=15) 151.13 23.778 
9. S.AST U/L    
 Control (n=17) 14.53 2.961 T=-2.700 
P>0.05 
Not Significant  
 Study (n=15) 18.13 4.518 
 
 
TABLE 12: STATISTICAL ANALYSIS OF S. sCD40L, S.CK-MB,LIPID PARAMETERS AND 
S.LDH,S.AST IN IN CONTROLAND STUDY GROUP 
FOR THE AGE GROUP OF 51 TO 60 YEARS 
 
SL.NO VARIABLES MEAN S.D STATISTICAL INFERENCE 
1. S.sCD40L ng/ml    
 Control (n=14) 1.44529 .136366 T=-5.823 
P<0.001 
Significant 
 Study (n=16) 4.58937 2.011897 
2. S.CK-MB U/L    
 Control (n=14) 15.29 4.531 T=-7.306 
P<0.01 
Significant 
 Study (n=16) 53.13 18.871 
3. S.TC mg/dl    
 Control (n=14) 165.50 18.430 T=-9.606 
P<0.001 
Significant 
  Study (n=16) 256.56 30.956 
4. S.TGL mg/dl    
 Control (n=14) 125.79 25.399 T=-6.175 
P<0.001 
Significant 
 Study (n=16) 199.06 37.464 
5. S.HDL-C mg/dl    
 Control (n=14) 44.14 9.223 T=3.890 
P<0.05 
Significant 
 Study (n=16) 34.63 3.117 
6. S.LDL –C mg/dl    
 Control (n=14) 96.93 19.329 T=-8.156 
P<0.001 
Significant 
 Study (n=16) 183.25 35.179 
7. S.VLDL –C mg/dl    
 Control (n=14) 25.14 5.082 T=-5.833 
P<0.001 
Significant 
 Study (n=16) 38.69 7.264 
8. S.LDH U/L    
 Control (n=14) 138.29 16.241 T=-2.641 
P>0.05 
Not Significant 
 Study (n=16) 159.31 25.588 
9. S.AST U/L    
 Control (n=14) 13.79 2.636 T=-3.185 
P>0.05 
Not Significant 
 Study (n=16) 18.81 5.357 
          TABLE 13: STATISTICAL ANLYSIS OF S. sCD40L, S.CK-MB, LIPID PARAMETERS AND S.LDH, S.AST 
IN  CONTROL AND STUDY GROUP FOR 
                           ABOVE 60 YEARS OF AGE 
SL.NO VARIABLES MEAN S.D STATISTICAL INFERENCE 
1. S.sCD40L ng/ml    
 Control (n=13) 1.44523 0.136242 T=-5.262 
P<0.001 
Significant  
 Study (n=16) 4.79875 2.286681 
2. S.CK-MB U/L    
 Control (n=13) 13.54 3.526 T=-6.482 
P<0.01 
Significant  
 Study (n=16) 62.63 27.026 
3. S.TC mg/dl    
 Control (n=13) 167.08 15.108 T=-6.549 
P<0.001 
Significant  
 Study (n=16) 263.69 51.253 
4. S.TGL mg/dl    
 Control (n=13) 125.23 28.856 T=-3.438 
P<0.05 
Significant  
 Study (n=16) 179.56 50.578 
5. S.HDL-C mg/dl    
 Control (n=13) 47.38 8.761 T=5.211 
P<0.001 
Significant  
 Study (n=16) 34.31 4.453 
6. S.LDL –C mg/dl    
 Control (n=13) 94.62 18.768 T=-7.129 
P<0.001 
Significant  
 Study (n=16) 193.50 46.930 
7. S.VLDL –C mg/dl    
 Control (n=13) 25.08 5.722 T=-3.404 
P<0.05 
Significant  
 Study (n=16) 35.88 10.184 
8. S.LDH U/L    
 Control (n=13) 136.92 8.261 T=-.414 
P>0.05 
Not Significant  
 Study (n=16) 138.63 12.800 
9. S.AST U/L    
 Control (n=13) 16.15 2.609 T=1.098 
P>0.05 
Not Significant  
 Study (n=16) 15.00 2.966 
             
 
 
  TABLE 14  : CORRELATION OF VARIABLES WITH DURATION OF  
                              CHEST PAIN IN THE STUDY GROUPS 
                                           
SL.NO VARIABLES DURATION MEAN S.D STATISTICAL 
INFERENCE 
1. 
 
 
S.sCD40L(ng/ml) 
 
3Hours(n=11) 2.66500 1.820541 P<0.001 
Significant 4Hours((n=17) 4.19553 1.32895 
5Hours(n=5) 5.90920 1.381516 
6Hours(n=17) 5.27612 1.771021 
2. S.CK-MB U/L 3Hours(n=11) 35.73 27.897 P<0.01 
Significant 4Hours(n=17) 58.71 17.211 
5Hours(n=5) 76.80 13.442 
6Hours(n=17) 60.53 16.938 
3. S.LDH U/L 3Hours(n=11) 150.64 28.779 P>0.05 
Not Significant 4Hours(n=17) 153.71 24.057 
5Hours(n=5) 141.80 12.518 
6Hours(n=17) 144.94 18.397 
4. S.AST U/L 3Hours(n=11) 17.82 5.288  
P>0.05 
Not Significant 
4Hours(n=17) 18.41 4.529 
5 Hours(n=5) 14.40 2.074 
6Hours(n=17) 15.94 4.548 
 
 
 
 
 
 
 
 
 
 
 
      TABLE 15: PEARSON CORRELATION BETWEEN S. sCD40L AND OTHER 
                       BIOCHEMICAL  PARAMETERS IN STUDY GROUPS 
 
 
S.sCD40L ng/ml CORRELATION VALUE STATISTICAL INFERENCE 
S.CK-MB U/L 0.777** p<0.01 Significant 
S.TC mg/dl 0.693
** 
p<0.01Significant 
S.TGL mg/dl 0.596
** 
p<0.01 Significant 
S.HDL mg/dl -0.637
** 
p<0.01Significant 
S.VLDL mg/dl                  0.586
* 
p<0.01 Significant 
S.LDL mg/ml 0.620
** 
p<0.01Significant 
S.LDH U/L                 -0.081 p>0.05Not Significant 
S.AST U/L                 -0.031 p>0.05 Not Significant 
 
 
 
 
 
 
 
 
 
  
1. SCATTER DIAGRAM OF S.sCD40L VS S. CK-MB IN CONTROLS 
 
0
5
10
15
20
25
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8
C
K
M
B
 (
U
/L
)
SCD 40L (ng/ml)
CKMB
 
 
       2.SCATTER DIAGRAM OF S.sCD40L VS S. CK-MB IN STUDY GROUPS 
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3SCATTER DIAGRAM OF S. sCD40L VS S. TC IN CONTROLS 
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4 SCATTER DIAGRAM OF S. sCD40L VS S. TC  IN STUDY GROUPS 
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5.SCATTER DIAGRAM OF S.sCD40L VS S. TGL INCONTROL GROUPS  
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6.SCATTER DIAGRAM OF S. SCD40L VS S. TGL IN STUDY GROUPS 
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         7.  SCATTER DIAGRAM OF S.sCD40L VS S. HDL IN CONTROLS 
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8.SCATTER DIAGRAM OF S. sCD40L VS S. HDL IN STUDY GROUPS 
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RESULTS 
  A total of 100 subjects were included in the present study . Out of this 50 were 
under the study group ( patients with ACS) and other 50 were under the control group, 
healthy individuals 20 females and 30 males were included in the study and control 
group. The values obtained in control and study group are presented in the master chart 
I&II respectively. 
The serum levels of sCD40L and serum lipid parameters, fasting blood sugar , 
blood urea, serum creatinine, serum CK-MB, Serum LDH, Serum AST, S.VLDL, 
S.LDL-C levels were estimated in control and study group. 
Table 1 shows the anthropometric  features, the biochemical data , results of 
Serum sCD40L quantification, Serum CK-MB levels in the control and study groups. 
Serum sCD40L levels were in the range of 1.216 ng/ml to 1.691 ng/ml with a mean of 
1.422 ng/ml in the control group. 
 Serum sCD40L levels in the study group ranged from 1.376 ng/ml to 8.099 ng/ml 
with a mean of 4.39758 ng/ml which is higher than the control group mean level. 
 Serum CK-MB in the control group ranged from 5 U/L to 22U/L with a mean of 
13.48U/L . In the study group Serum CK-MB level ranged from  14 U/L to 105 U/L with 
a mean of 56.08 U/L which is higher than the control group mean level. 
 
Table 2 shows age and sex distribution among study and control group subject ( 30 
males and 20 females in each group) not significant in control groups (P=0.914>0.05) 
significant in study groups(P=0.035<0.05) . 
Table 3 shows serum mean sCD40L levels in control and study group. Mean 
serum sCD40L level in study group is( 4.397 ng/ml) which is higher than the control 
group mean of ( 1.422 ng/ml) which is statistically significant                       ( 
P=0.0001<0.05) 
Table 4 shows lipid parameters in study and control group there is a statistical 
elevation of S.TC, S.TGL, S.VLDL, S.LDL-C, in study group compared to control 
(P=0.0001<0.05) there is statistically significant decrease in the  S.HDL-C levels in the 
study group compared to control group (P<0.001).  
 Table 5 shows mean Serum CK-MB values in study and control group. There is a 
statistically significant increase in the mean of study group (56.08± 22.58 U/L) compared 
to control group (13.48±4.047 U/L); (P <0.05).Compared to the values of Serum  
sCD40L the increase in values of  Serum CK-MB does not show much significance.  
Table 6 shows mean Serum sCD40L level in male control and study groups . 
There is a statistically significant increase in the mean of Serum sCD40L level in study 
group (4.569±1.670 ng/ml) compared to control group(1.442±0.151), (P=0.0001<0.05). 
Table 7 shows mean Serum sCD40L level in female control and study groups. 
There is a statistically significant increase in the mean level of serum sCD40L  in study 
group(4.139±2.227 ng/ml) compared to control group(1.392±0.117 
ng/ml),(P=0.0001<0.05). 
Table 8 and 9 shows Serum sCD40L, Serum lipid parameters and Serum CK-MB 
levels in male and female groups respectively. Serum sCD40L, Serum lipid parameters 
and Serum CK-MB levels are high in study group compared to the control group both in 
males and females which is statistically significant. 
Tables 10-13 shows age-wise statistical analysis of Serum sCD40L, Serum lipid 
parameters and Serum CK-MB, Serum LDH, Serum AST levels in control and study 
group.  
Table 14 shows the statistical analysis of Serum sCD40L, Serum CK-MB, Serum 
LDH, Serum AST and duration of chest pain in the study group.. 
Table 15 shows Pearson’s coefficient of correlation between Serum sCD40L and 
other biochemical parameters in study group. 
 There is a significant positive correlation between Serum sCD40L and Serum 
CK-MB, Serum TC, Serum TGL, Serum LDL-C, Serum VLDL and a negative 
correlation between Serum sCD40L and Serum HDL-C which is statistically significant. 
No significant correlation was found between Serum sCD40L with Serum LDH and 
Serum AST. 
Bar Diagram  I shows age and sex distribution of control and study groups.. 
Bar Diagram II shows mean Serum sCD40L levels in control and study groups. 
Bar Diagram III shows Serum lipid parameters between control and study groups. 
Bar Diagram IV shows mean Serum CK-MB levels in control and study groups. 
Bar Diagram V shows mean Serum sCD40L level in male control and study groups.  
Bar Diagram VI shows mean Serum sCD40L level in female control and study groups. 
1. Scatter diagram of serum sCD40L vs Serum CK-MB levels in controls. 
2. Scatter diagram of serum sCD40L vs Serum CK-MB levels in study groups. 
3.  Scatter diagram of serum sCD40L vs Serum TC levels  in control groups. 
4. Scatter diagram of serum sCD40L vs Serum TC levels in study groups. 
5. Scatter diagram of serum sCD40L vs Serum TGL levels in control groups. 
 
 
6. Scatter diagram of serum sCD40L vs Serum TGL levels in study groups. 
7. Scatter diagram of serum sCD40L vs Serum HDL-C levels in control groups. 
8. Scatter diagram of serum sCD40L vs Serum HDL-C levels in study groups. 
DISCUSSION 
       The present study was done to evaluate levels of Serum sCD40L in patients with 
Acute Coronary Syndrome. It is a powerful biochemical inflammatory  marker. .  
  In our study mean age of study group is (55.56±9.528 years) and that of control 
group is (52.22±9.412 years), mean BMI of study group and control group are equal and 
there is no statistical significance(25.295 versus 25.349, P>0.05). 
     In the present study mean serum sCD40L level of study group is higher than the 
control group (4.397±1.903 ng/ml versus 1.422±0.1395 ng/ml) which is statistically 
significant (P<0.05).This findings are in accordance with the study of  Valerio sanguigni 
et al, (4.181±2.07 ng/ml in study group versus 2.60 ±0.7 ng/ml in control groups)(7). 
In our study the mean level of serum sCD40L in ACS cases is (4.397±0.17 ng/ml) 
. This finding is almost consistent with Pal Aukurst et al study and Priya Gururajan et al 
study, reported higher levels of Serum sCD40L in ACS patients.  
The mean Serum cholesterol level of (262.12±39.723 mg/dl) in the study group is 
higher than the control mean Serum cholesterol level of (166.98±17.757 mg/dl) which is 
statistically significant (P<0.05). This level is slightly higher than the mean level of 
Serum cholesterol observed in a study done by Priya Gururajan et al, and Mari Luomala 
et al(78). 
The study group .mean Serum TGL level is  (185.04±43.413 mg/dl) which is 
higher than the control group mean of 124.76±23.671 mg/dl which is statistically 
significant(p<0.05). Serum TGL level increases from 90 mg/dl to 180 mg/dl is associated 
with the doubled the incidence of CAD(79,80,81) 
         Mean Serum HDL cholesterol in the control and study group are 
(43.24±9.905mg/dl and 34.16±3.883 mg/dl) respectively. The mean serum HDL-C level 
in the study group is lower than the control group. It is statistically significant (p<0.05). 
Similar values are observed in Yogendra singh et al , study and demonstrated that low 
Serum HDL-C increases the risk of CAD..    
The present study mean Serum LDL cholesterol of study group is higher than the 
control group (191.16±40.132 mg/dl versus 98.90±21.367 mg/dl ) which is statistically 
significant(p<0.05). Raised Serum LDL cholesterol has been recognized as a primary risk 
factor for CAD(81). 
The mean level of Serum CK-MB value in the study group is higher than the mean 
level of Serum CK-MB in control groups (56.08±22.58 U/L versus 13.48±4.04 U/L).  
The mean level of Serum sCD40L in males of the study group is higher than to the 
mean level of Serum sCD40L in males of the control group (4.569±1.670 ng/ml versus 
1.442±0.151 ng/ml) which is statistically significant (p<0.05). 
The mean level of Serum sCD40L in females of the study group is higher than to 
the mean level of Serum sCD40L in females of the control group (4.139±2.227 ng/ml 
versus 1.392±0.117 ng/ml) which is statistically significant (p<0.05).There is significance 
difference in the mean values of lipid  parameters, sCD40L and CK-MB in  male and 
female groups.   
Present study shows that there is significant increase in level of Serum sCD40L 
level in all age groups. Serum CK-MB shows not that much significance in comparison 
with Serum sCD40L levels. 
 Serum TC increase in all age groups (<40 years, 41-50 years, 51-60 years, 60 
years). Serum TGL shows increased values in all age groups. Serum HDL-C does not 
show significant decrease under 40 years, but its values are significantly decreased in the 
age group of (41-50, 51-60, >60 years). 
 Serum LDL-C levels are also significantly raised  in all age groups. VLDL-C 
values are not that much raised in <40 years but it is markedly elevated in remaining age 
groups. These variations can be attributed to the modifiable and non modifiable risk 
factors of atherosclerosis. Serum LDH and Serum AST values are not that much raised in 
all age groups.  
There is a significant early rise in Serum sCD40L levels before Serum CK-MB, 
where as  Serum LDH and Serum AST shows non significance     
 Pearson coefficient correlation analysis in the study group shows there is a highly 
significant positive correlation between Serum sCD40L and   
    S.CK-MB=(r=0.777, p<0.01) 
   S.TC=(r=0.693, p<0.01) 
   S.TGL=(r=0.569, p<0.01) 
There is negative correlation between Serum sCD40L and Serum HDL-C which is 
statistically significant (r=-0.637 p<0.01)(82.83). 
Serum sCD40L contributes to atherosclerotic plaque destabilization and 
progression of chemokines, growth factors, cytokines and procoagulant factors in various 
cell types associated with atheroma. For thrombus formation, platelet activation is 
important, which in turn leads to precipitation of most of the unstable coronary 
syndromes. 
Michelson AD et al found that large amounts of Serum sCD40L are produced and 
released from activated platelets. Yan et al in their study, demonstrated correlation 
between sCD40L and platelet activation. They also found that in patients with CAD, 
Serum sCD40L levels indicate an independent increased risk of major adverse 
cardiovascular events. 
 
 
         
 
                                
                                         CONCLUSION 
 
Biochemical markers such as Serum  CK-MB, cardiac Troponin-I, and Myoglobin 
are used in the clinical setting to asses MI. However , elevation of these markers indicate 
myocardial necrosis and in the absence of necrosis these markers are not elevated . Serum 
sCD40L is a marker of inflammatory thrombotic activity that is expressed within 
seconds, after platelet activation. 
Platelet activation and elevated fibrinogen level are associated with increased risk 
of Coronary thrombosis which is the gravest complication of atherosclerosis. 
Since ACS is complicated by both myocardial necrosis and inflammation, 
assessment of both the processes may allow a better assessment of the disease. 
  Early intervention using anti-inflammatory drugs can be tried to prevent the 
progression of infarct size. This helps in reducing the morbidity and mortality from acute 
coronary syndrome.  
 
 
            
                        
                                  LIMITATIONS OF THE STUDY 
 
Serum sCD40L when coupled with coronary angiography would have aided in 
assessing the severity of coronary stenosis. 
Analysis of genetic polymorphism in sCD40L would have enabled discrimination 
of various iso forms and their association with CAD.  
                          FUTURE SCOPE OF THE STUDY 
 
Serum sCD40L level estimation in outpatient department itself can be studied in 
patients  complaining of chest pain to rule out myocardial ischemia before ECG 
manifestation. 
It can be used to rule out non anginal causes of chest pain. 
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A STUDY OF SERUM SOLUBLE CD40 LIGAND LEVEL IN PATIENTS 
          WITH ACUTE CORONARY SYNDROME – PROFORMA 
                                                                                                                   O.P/I.P.NO: 
Name of the patient                         : 
Age/sex                                            : 
Occupation                                       : 
Address                                            : 
 
 
Complaints                                        :     
Past history                                        :  
 
Personal history                                :  
 
Family history                                   : 
Drug history                                      : 
General examination                         :       Ht:   (mts )         Wt: (kg)           BMI: 
(kg/mt2) 
 
                                                                   BP:     (mmHg)     Pulse rate:   /minute 
 
 
 
Specific examination                         :      CVS:                            RS: 
                                                                 ABD:                             CNS: 
 
Investigations: 
1.  Blood sugar (fasting):                 mg/dl 
 
2. Blood urea:                                  mg/dl 
 
3. Serum creatinine:                        mg/dl 
 
      4. Serum soluble CD40 Ligand:      ng/ml  
      5. Lipid profile: 
        S. Total cholesterol:                       mg/dl 
        S. Triglycerides:                             mg/dl 
        S. HDL-C:                                     mg/dl 
        S.VLDL-C:                                    mg/dl 
        S. LDL-C:                                      mg/dl 
      6. Serum CK-MB:                            U/L 
      7. Serum LDH:                                 U/L 
      8. Serum AST:                                  U/L 
 
 
 
 
 
 
                                                CONSENT FORM  
  
             Dr.M.Manonmani post graduate student in the department of Biochemistry, 
Thanjavur Medical College, Thanjavur  is doing  A Study of Serum Soluble CD40 
Ligand Level in Patients With Acute Coronary Syndrome. The procedures has been 
explained to me clearly. I hereby give my consent to participate in this study. The data 
obtained here may be used for research and publication. 
  
Signature: 
Name: 
Place: 
 
